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Resumo 
Figurando no topo da lista de preocupações por parte da Organização Mundial 
de Saúde, a resistência a antibióticos é, na actualidade, um dos maiores entraves à 
saúde pública. Infecções causadas por estirpes resistentes de bactérias como 
Mycobacterium tuberculosis, Staphylococcus aureus e Streptococcus pneumoniae são 
cada vez mais difíceis de tratar e controlar, sendo de extrema urgência encontrar 
novos compostos que substituam os antibióticos ineficientes e combatam o aumento 
de super microrganismos. A obesidade é também um dos principais problemas de 
saúde mundial, sendo considerada uma das doenças metabólicas mais prevalentes. 
Devido à falta de compostos para tratar esta enfermidade e à ineficiência dos já 
existentes, novos medicamentos são necessários para combater o aumento 
exponencial da população obesa.  
Numa tentativa de superar esta necessidade de metabolitos inovadores, as 
atenções estão a ser focadas nos oceanos, uma inesgotável fonte de biodiversidade. 
Um dos grupos de bactérias menos estudados mas promissor, os Planctomycetes, são 
um filo que pertence ao super filo PVC. Possuem ciclos de vida complexos, grandes 
genomas e podem colonizar quase todos os habitats, inclusive já sendo encontrados a 
viver em associação com organismos marinhos como macroalgas. Estas 
características, em conjunto com o seu potencial genético para produção de 
metabolitos secundários, torna-nos em fortes candidatos para a descoberta de novos 
compostos.  
O objectivo deste trabalho foi explorar o potencial dos metabolitos secundários 
produzidos por várias estirpes aquáticas de Planctomycetes, sendo a maioria isolada a 
partir do complexo e competitivo biofilme de macroalgas, com enfâse na procura de 
actividade antimicrobiana contra diferentes microorganismos (Bacillus subtilis, 
Micrococcus luteus e Chlamydia trachomatis) e possível actividade anti obesidade. 
Paralelamente, pretendeu-se desenvolver e optimizar protocolos para o cultivo de 
Planctomycetes, preparação de extractos e isolamento de moléculas bioactivas.    
Neste estudo, a actividade antimicrobiana foi rastreada usando vários ensaios 
diferentes e diversos protocolos para preparação das culturas e consequente 
extracção de metabolitos foram estados. Extractos obtidos de estirpes pertencentes a 
diversas espécies de Planctomycetes, como Rhodopirellula baltica (MsF2 e FF1), 
Rhodopirellula rubra (UC9), Aquisphaera giovannonii (OJF8) e Rubinisphaera 
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brasiliensis (Gr7), usando um protocolo de extracção com acetato de etilo, 
demonstraram atividade antimicrobiana contra B. subtilis e M. luteus. Os ensaios que 
avaliaram a actividade contra o agente patogénico C. trachomatis e a actividade contra 
obesidade demonstraram resultados promissores, mas estudos adicionais serão ainda 
necessários. No entanto, apesar da elevada biodiversidade de rastreios e técnicas de 
extracção testadas, não foi possível obter um protocolo optimizado que permitisse o 
isolamento de moléculas bioactivas de Planctomycetes usando cromatografia de 
permeação em gel.  
Este trabalho confirmou a capacidade dos Planctomycetes produzirem 
metabolitos antimicrobianos efectivos contra bactérias Gram positivo bem como o 
potencial contra o parasita intracelular C. trachomatis e estender o nosso 
conhecimento a metabolitos com capacidade anti obesidade. Infelizmente, devido a 
inconsistências de resultados e a adversidades metodológicas, não foi possível o 
passo subsequente, o do isolamento de moléculas bioativas.  
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Abstract 
 
 Antibiotic resistance is a major actual problem, placed at the top of the list of 
concerning of world’s health by the World Health Organization (WHO). Dangerous 
bacterial infections caused by organisms like Mycobacterium tuberculosis, 
Staphylococcus aureus and Streptococcus pneumoniae are becoming increasingly 
more difficult to treat, making of extreme urgency to find new compounds that can 
substitute the inefficient ones and combat the new rising super bugs. Another main 
health problem is obesity, one of the most prevalent metabolic diseases. The lack of 
drugs with obesogenic effect and the inefficiency of the existing treatments make it 
necessary to find new compounds in order to combat the increase of obese population.  
 To overcome the need of innovative metabolites, attentions are being paid in 
the endless source of biodiversity: the oceans. One of the less studied and promising 
group, the bacterial phyla Planctomycetes, belongs to the PVC super-phylum. They 
possess large genomes, complex life cycles and can colonize most habitats, as for 
instance the biofilm of certain marine organisms, such as macroalgae. These 
characteristics along with their genetic potential in secondary metabolites point them as 
good candidates for the discovery of new drugs.  
 The objective of this study was to explore the secondary metabolite potential of 
several strains of marine and freshwater Planctomycetes, the majority of them isolated 
from the complex and competitive biofilm of macroalgae, with emphasis on the search 
of possible antimicrobials against different targets (Bacillus subtilis, Micrococcus luteus 
and Chlamydia trachomatis) and possible anti-obesogenic activity. At the same time, it 
was envisaged to develop and optimize protocols for the culturing of Planctomycetes, 
extracts preparation and isolation of bioactive molecules.  
 Various different antimicrobial screening assays and several culturing and 
extractions preparation protocols were assayed in this study. Bioactivity was observed 
against B. subtilis and M. luteus for extracts obtained from different Planctomycetes 
species, Rhodopirellula baltica (MsF2 and FF1), Rhodopirellula rubra (UC9), 
Aquisphaera giovannonii (OJF8) and Rubinisphaera brasiliensis (Gr7), following a 
protocol of extraction with ethyl acetate. Assays that evaluated anti-Chlamydia 
trachomatis and anti-obesity activity by Planctomycetes metabolites showed promising 
results, but additional studies are needed. However, besides the high diversity of 
screening approaches and extraction techniques assayed, it was not possible to 
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achieve a good optimized protocol that allowed the bioactive molecules isolation from 
Planctomycetes through gel permeation chromatography.  
 This work confirmed the capacity of Planctomycetes to produce antimicrobial 
metabolites effective against Gram positive bacteria as well as the potential against the 
intracellular parasite Chlamydia trachomatis and extended our knowledge on potential 
metabolites against obesity. Unfortunately, due to results inconsistencies and 
methodological adversities we were not able to step forward towards bioactive 
metabolite isolation.  
 
Key words 
 
Bacteria; Antibiotic resistance; Planctomycetes; Secondary metabolites; Extraction of 
bioactive compounds; Antimicrobial activity; Anti-obesogenic activity. 
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Introduction 
 
Development of a new drug is an extensive, complex but necessary 
interdisciplinary process. It involves numerous procedures, beginning with a discovery 
or synthesis of a new compound and going from steps such as pre-clinical trials with 
animals to formulation and clinical trials with humans, to serve one propose: human 
safety and health. 
 One of the biggest concerns in the current time is antimicrobial resistance (AR). 
Without an effective antimicrobial agent against several pathogens, some infections 
can spread quickly through the population and lead to illness and death, but one of the 
main complications is the compromised safety of numerous medical procedures. Due 
to infections, several practices like organ transplants, caesarean, cancer chemotherapy 
and surgeries in general can become more unsafe, needing prolonged and costlier 
care. Together with antivirals, antifungals and anti-parasites, antibiotics are losing 
activity due to resistance, normally resulting from the co-evolution between host and 
pathogen through genetic variations within the population, both facilitated by the small 
cycles of life that allows bacteria to quickly change. However, these resistances can 
and are being accentuated by the overuse and/or the incorrect use of the medicines 
together with the poor sanitary conditions around the globe that help increasing the 
velocity of the spread. According to the World Health Organization (WHO), the 
following pathogens (and respective resistances) are of international importance in the 
current times (WHO, 2014): Escherichia coli – resistance to third-generation 
cephalosporins and to fluoroquinolones; Klebsiella pneumoniae – resistance to third-
generation cephalosporins and to carbapenems; Staphylococcus aureus – resistance 
to methicillin; Streptococcus pneumoniae – resistance (non-susceptibility) to penicillin; 
Non-typhoidal Salmonella – resistance to fluoroquinolones; Shigella species – 
resistance to fluoroquinolones, Neisseria gonorrhoeae – decreased susceptibility to 
third-generation cephalosporins and Mycobacterium tuberculosis – resistance to 
rifampicin. The impact of these microorganisms varies from hospital and community 
areas to food market and due to the lack of new compounds to substitute the ones 
there are no longer efficient, research, innovation and inspiration are required in order 
to fight against these new rising super bugs and help in its dispreads. Sexual 
transmittable diseases are also of enormous concern. Chlamydial infections (caused by 
the microorganism Chlamydia trachomatis) are one of the most common worldwide. 
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Patients are mostly asymptomatic (which favors the continuous spreading of the 
disease) and often develop other types of infections at the same time. Women are 
more susceptible and even after treatment can gain serious complications as infertility, 
ectopic pregnancy and chronic pelvic pain. Antibiotics like azithromycin and 
doxycycline can treat uncomplicated infections (Malhotra et al., 2013), but persistent 
ones are more problematic. Chlamydiae are obligate intracellular bacteria and under 
stress conditions can change to atypical forms (aberrant bodies): these are non-
infectious, have reduced metabolic activity and do not replicate, yet remain alive. This 
type of forms has a decrease in the lipopolysaccharide (LPS) antigens, making 
diagnosis difficult, but maintains a high production of chlamydial heat shock protein 60 
(hsp60), which induces chronic inflammation. This form also has decreased levels of 
chlamydial major outer membrane protein (MOMP), which leads to reduced transport of 
antibiotic across the cell, resulting in failure of treatment in most of the patients with 
chronic infections (Malhotra et al., 2013). Also, there are already evidences of 
multidrug resistant C. trachomatis in women with high bacterial load (Horner 2016), 
which makes the search for new anti-chlamydia compounds a priority. 
Antibiotics normally function by interfering with important pathways within the 
bacteria and which specific cellular targets are not present in eukaryotic cells, to insure 
that only these microorganisms are affected. They can act directly against a specific 
enzyme or by disrupting other important cellular processes through a specific mode of 
action (Urban et al., 2007). Cell wall, nucleic acids and protein biosynthesis are the 
most common cellular targets. Cell wall biosynthesis has always been one of the most 
appellative one, due to the importance of the peptidoglycan layer in bacterial protection 
and its absence in eukaryotic cells. With this action, B-lactam compounds are an 
example of one of the most important antibiotics discovered: penicillin (Rang et al., 
2015). The cell wall as a target is also important for the differentiation between types of 
antibiotics, according to their range of action. Broad-spectrum antibiotics act against a 
wide range of bacteria, normally both Gram positive and Gram negative. On the other 
hand, there are antibiotics more specific for a selected group. This selectivity is often 
based on the differential cell wall composition between the various types of bacteria. 
Cell division is also necessary for maintaining and producing new bacterial cells, which 
makes both nucleic acids (deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)) 
synthesis important targets as well. For example, rifampicin blocks initiation of RNA 
synthesis by specifically inhibiting bacterial RNA polymerase and it does not interact 
with mammalian RNA polymerases, making it specific for bacteria. On another hand, 
quinolones are a key group of antibiotics that specifically interfere with bacterial 
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topoisomerase II (important cell cycle enzyme) and not with mammalian 
topoisomerases. Fluoroquinolones are the second-generation quinolones (which 
include levofloxacin, norfloxacin, and ciprofloxacin) are also an example of compounds 
that act against this target as well (Rang et al., 2015). Protein synthesis is also a main 
target, since most important cellular processes need enzymes. Tetracyclines, such as 
doxycycline, prevent the binding of aminoacyl-tRNA by blocking the A (aminoacyl) site 
of the 30S ribosome, for example.  
Besides antibiotic resistance and non-controlled infections, another main 
problem against the human health is, currently, obesity. One of the most prevalent 
metabolic diseases, obesity is the designation of the condition of presenting a body 
mass index (BMI) above 30 kg/m2. Individuals who have a high level of body mass (and 
even more the ones in morbid obesity stage, with BMI above 40 kg/m2 (WHO, 2000)) 
are associated with other health complications, as cardiovascular diseases (mainly 
heart disease and stroke) diabetes, musculoskeletal disorders (especially osteoarthritis 
– a highly disabling degenerative disease of the joints) and some cancers (including 
endometrial, breast, ovarian, prostate, liver, gallbladder, kidney, and colon), as was 
observed by the WHO (WHO, 2000). Besides, all patients who suffer this condition 
need continuous care, making the entire healthcare costlier. Obesity is a complex 
condition dependent on many factors, tough  individual responses may be enough in 
some cases to decrease the body mass in excess, as lower the food intake, increase 
the physical activity and eat healthier foods (with lower salt/sugar composition). 
However, metabolic disturbances may prevent the resolution of the problem, making 
anti-obesogenic drugs necessary to complement the process. The lack of compounds 
with this effect is noticed, as only a few medications are currently on the market (Birari 
et al., 2007). Existing treatments work mostly by two different mechanisms of action: 
appetite suppression and interference with the body’s ability to absorb specific 
nutrients. The drugs most commonly used for this are catecholamines, like 
amphetamines, and anti-depressants like bupropion (Bray, 1993). On the other hand, 
orlistat is the drug usually recommended for inhibition of the absorption of fat, being an 
inhibitor of the enzyme lipase in the intestine (Weibel et al., 1987). However, no 
treatment is currently entirely efficient, having also frequent gastrointestinal side 
effects, mostly in infants and adolescents (Viner et al., 2010). Thus, new drugs with 
obesogenic effect are needed in order to combat the increase of the obese population.  
Since the ancient times, the discovery of new drugs has always been a priority 
for humans, even if in a non-rational way.  Nature was the main local to search for 
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substances that could cure, relieve pain or even increase the wellbeing in general. 
However, with the advance of technology, the structures of the bioactive compounds 
were more and more known, changing completely the way that this discipline was 
seen. Diversity and complexity were the compounds main features, even with some 
common bases: aromatic rings, heterocyclic structures, carboxylic acids, esters and 
chirality were the most present characteristics. Also, the elements that constituted 
those bio metabolites were essentially the same: carbon, oxygen, hydrogen, nitrogen, 
sulfur and halogenates such as chloride and fluorine. With the knowledge of the 
structures, semi-synthesis was the subsequent step, with the objective of optimization 
of production (since the total chemical synthesis of compounds similar to natural ones 
was almost impossible due to the complexity). However, with advances in chemistry, 
the search for new compounds in Nature was particularly slightly overlooked in favor of 
a new era of laboratorial drug synthesis. Improvements of knowledge in Biology and 
Biochemistry also allowed to do directed and rational search, permitting discoveries 
based on specific targets or processes, lowering aleatory developments. Currently, with 
the lack of new drugs, Nature is coming back again as a main source of discovery, 
thanks to the inexhaustible biodiversity, bioavailability and strength of compounds that 
it can give us. With this change, the attentions also started to be directed to the less 
explored marine environments (Bhatnagar & Kim, 2012). The biodiversity of living 
beings is high in terrestrial habitats and consecutively, the diversity of metabolites 
produced but the variety in aquatic habitats is enormously higher and much more 
unexplored. Chordates, Plants, Molluscs, Crustaceans, Insects, Algae, Nematodes, 
Fungi and Bacteria: they all compete for resources and it is plausible that the 
production of metabolites is intense and with a large variety of actions. Regardless of 
the complications of using natural compounds from marine environments (toxicity, high 
amount of samples needed in several cases and difficulty of extraction), in the past 
years numerous drugs with origin in aquatic habitats and, more specifically, from 
microorganisms, which are simpler to cultivate and maintain, have been approved 
(Desjardine et al., 2007 and Eom et al, 2013). 
Planctomycetes is a phylum of bacteria that phylogenetically belongs to the 
PVC super-phylum, along with Verrucomicrobia, Chlamydia and Lentisphaerae 
(Wagner & Horn, 2016). Considered one of the deepest branches of bacterial phyla, 
this still unexplored phylum has very particular and uncommon characteristics, like a 
unique complex system of membranes (Fuerst 2013 and Lage et al., 2013) (Fig. 1).  
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During many years, the cell wall of Planctomycetes was thought to be 
peptidoglycan free, which placed these bacteria under discussion on a possible 
eukaryotic cell ancestry (Fuerst & Sagulenko, 2011). Peptidoglycan, or murein, is a 
complex molecular structure with the function of structural strength and cell protection, 
a polymer consisting of glycan strands and amino acids. The sugar strands are made 
up of N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) residues, 
alternated and cross-linked by short peptides, whose composition is most often l-Ala-γ-
d-Glu-meso-A2pm (or l-Lys)-d-Ala-d-Ala (A2pm, 2,6-diaminopimelic acid) (Vollmer et 
al., 2008). Due to the important role in bacterial cells, murein is also one of the main 
targets of antibiotics, like the familiar example of penicillin (Rang et al., 2015). The 
absence of this vital compound in cell walls, only observed in a scarce group of 
bacteria, has always been intriguing, but recent studies have showed clear evidences 
that the cell wall of Planctomycetes do possess, in fact, peptidoglycan (Jeske et al., 
2015; Van Teeseling et al., 2015). It is located in a layer underneath the outer 
membrane, which combines with the typical characteristics of Gram-negative bacteria, 
clarifying the mystery of that supposed differential cell wall composition. 
Planctomycetes are also resistant to β-lactam antibiotics, due to the production of β-
lactamases (Jeske et al., 2015), explaining the resistance that was once attributed to 
Fig. 1- Ultrathin sections of a strain of Rhodopirellula rubra by transmission electron microscopy of cross sections (Lage 
et al., 2013), showing the unique complex system of membranes of Planctomycetes.   
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the lack of peptidoglycan. The other phyla belonging to PVC have also been under 
consideration and the same elucidation about the presence of peptidoglycan was made 
for bacteria from Chlamydia, including with a new metabolic cell-wall labelling method 
(Pilhofer et al., 2013; Kåhrström, 2014; Liechti et al., 2014). However, one common 
feature is notice: bacteria from both phyla lack the cytoskeletal protein FtsZ. This 
protein has been associated universally to cell division in bacteria with walls and 
classified as an essential peptide but these studies suggest new possible mechanisms 
of division. Although the constitution of the cell wall of planctomycetes has been 
elucidated, there are other peculiar details and characteristics remaining to explore and 
clarify. 
In an ecologically view, bacteria from the phylum Planctomycetes are found in 
most of the planet habitats, ranging from terrestrial, freshwater and marine 
environments (Lage & Bondoso, 2011; Lage & Bondoso, 2014) to more extreme ones, 
like glacial waters (Zeng et al., 2013), locals with a wide range of pollution (with 
hydrocarbons or others) (Akob et al., 2007; Halter et al., 2011) and hot springs 
(Bohorquez et al., 2012), demonstrating their capacity of survival and adaptation. They 
are mostly heterotrophic, aerobic, mesophilic and neutrophilic, with an extra group of 
anaerobic ammonium oxidation species (or anammox Planctomycetes) which are 
strictly chemolithotrophic (Fuerst & Sagulenko, 2011), showing also the variety of 
metabolisms. Some species were also found living associated with other organisms, 
such as macroalgae (Lage & Bondoso, 2011; Bondoso et al., 2014; Lage & Bondoso, 
2014), belonging of the three phyla: Chlorophyta (green algae), Rhodophyta (red 
algae) and Heterokontophyta (brown algae). The strains explored in this study are an 
example of that association, being previously isolated from the biofilm of several 
macroalgae from the Portuguese coast. Macroalgae can possibly benefit from the 
presence of microorganisms thanks to the compounds produced by them and the same 
in reverse, making a dynamic relationship (Lage & Bondoso, 2014). Diverse algal 
macromolecules can be nutritive substrates for Planctomycetes, like agar, alginate, 
cellulose and also sulfated polysaccharides, since the presence of sulfatases was 
observed and sulfatases genes were already found in Rhodopirellula baltica strains 
(Glockner et al., 2003; Wegner et al., 2013). On the other hand, molecules produced by 
Planctomycetes can, possibly, help algae to control of unwanted pathogens as well as 
reducing competition at the same time.   
Besides the uncommon features already exposed, in a first view, 
Planctomycetes seem to fit in the group of bacteria that possible produce compounds 
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with interest: (1) their cycle of live is long and complex, which is common among 
bacteria already studied for this purpose, like Actinobacteria (Streptomyces) and 
Myxobacteria (Jeske et al., 2013); (2) they possess large genomes; (3) they have a 
great capacity of adaptation; (4) they belong to an unexplored and independent branch, 
suggesting new molecules and (5) they live in a competitive and dynamic 
environmental where they can dominate against other bacteria that have a quicker 
cycle of live (which suggests that they possible have some strategy). Although some 
biochemical pathways are still unknown for this relatively understudied phylum, 
secondary metabolites with interest are starting to be explored. A genomic study about 
the presence of genes encoding modular polyketide synthases (PKS) and 
nonribossomal peptide synthetases (NRPS) was firstly performed to a variety of 
bacteria from different taxa (Donadio et al., 2007), in which the only Planctomycete 
genome available and analyzed corresponded to a strain affiliated with the species 
Rhodopirellula baltica. Its genome possesses genes encoding for two small NRPSs, 
two monomodular PKSs and a bimodular NRPS/PKS. PKS and NRPS are complex 
families of enzymes that ultimately lead to most of the bioactive secondary metabolites 
of interest (Donadio et al., 2007). PKS leads to the production of polyketides and NRPS 
catalyze important peptide products. The presence of genes encoding for these two 
groups of enzymes is therefore a possible indicator of production of metabolites with 
biotechnological interest. In Jeske et al., (2013), thirteen Planctomycetes genomes 
were analyzed through genome mining, with the use the software AntiSMASH (for 
antibiotic and secondary metabolite identification). One hundred and two candidate 
genes or clusters were found within the analyzed 13 genomes, confirming the genetic 
potential of this phylum. The potential by Planctomycetes was also confirmed by Jeske 
et al., (2016), where antimicrobial activity was demonstrated against several bacterial 
targets with extracts from Rhodopirellula baltica species. More Planctomycetes were 
later screened for the presence of genes encoding for NRPS/PKS and for antimicrobial 
activity with bioactivity studies (Graça et al., 2016). This study focused on exploring the 
potential of marine strains isolated from several macroalgae and affiliated to numerous 
species such as Rhodopirellula baltica, Rhodopirellula lusitana, Rhodopirellula rubra, 
Roseimaritima ulvae and Planctomyces brasiliensis. Almost all strains presented at 
least one of the genes referred and antimicrobial activity was observed for 43% of the 
strains against the fungus Candida albicans and 54% against the bacterium Bacillus 
subtilis. With the software NaPDos, a bioinformatics tool for the rapid detection and 
analysis of secondary metabolite genes, some strains were also screened for the 
potential pathway product that would be formed (Graça et al., 2016). Three strains 
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revealed potential to produce antimicrobial compounds, as myxalamid, bacitracin and 
pikromycin. This study confirmed the bioactive capacity of Planctomycetes, with 
emphasis on marine ones, to produce antimicrobial compounds and encouraged 
further studies envisaging molecule isolation and characterization for the possible 
discovery of new drugs.  
Recent studies also demonstrated that many natural products, including 
secondary metabolites from plants, cyanobacteria, fungi and phytoplankton, possess 
anti-obesity activities (Castro et al., 2016 and Yun 2010). Therefore, Planctomycetes 
are also promising sources of novel bioactive molecules with this effect. 
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Objectives 
 
This Master thesis was performed in the framework of the Masters in 
Biochemistry of Sciences Faculty from Porto University, Portugal, and it was developed 
in the Laboratory of Microbial Ecophysiology from University of Porto (LEMUP) and in 
the Institute for Pharmaceutical Microbiology from University of Bonn, Germany, as an 
Erasmus+ Internship. The objective of this study was to explore the secondary 
metabolite potential of several strains of marine and freshwater Planctomycetes, with 
emphasis on the search of possible bioactivity against different targets (antimicrobial 
and anti-obesity activity). At the same time, it was envisaged to develop and optimize a 
protocol for culturing of Planctomycetes and preparation of extracts (which 
comprehended several organic solvents and methodologies) for the obtainment of 
bioactive molecules. Another objective was the isolation of bio compounds by gel 
permeation chromatography as well as characterization of their mode of action using 
Bacillus subtilis reporter strains.  
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Methods  
1. Biological material  
 
Thirty-seven strains of several species from the phylum Planctomycetes were 
explored in this thesis, which belong to a collection from the Laboratory of Microbial 
Ecophysiology from University of Porto (LEMUP). Thirty-five of the strains came from 
marine environments, which were previously isolated from the biofilm of various marine 
macroalgae collected along the Portuguese coast (as described in Lage & Bondoso, 
2011). On the other hand, the remaining two were isolated from freshwater sediments 
(Bondoso et al., 2011). Besides the origins of the species and the phylogenetic 
diversity, this panel of strains was also selected by its previously reveled potential to 
produce metabolites with antimicrobial activity, observed in the studies performed 
during the internship realized in the Bachelor degree in Biology (unpublished studies) 
and by Graça et al., (2016). This potential was shown by genomic analyses (presence 
of PKS and/or NRPS genes and prediction pathway product using NaPDos software) 
and by preliminary bioactivity screenings in liquid medium. The numbering given to the 
isolates, their affiliation, their origin of isolation, the presence of PKS/NRPS genes and 
the potential pathway product prediction are all described in Table 1. The appearance 
of these Planctomycetes is very characteristic and easy to distinguish: in general, they 
form circular, small, convex and translucent colonies ranging from light pink to almost 
red in color, which is demonstrated in Fig. 2, where two of the chosen strains are 
exemplified. One of the strains from the panel, although, is orange pigmented (strain 
Gr7). 
 
 
 
 
 
 
 
 
Fig. 2- Colonies of strains MsF2 and Gtu1, respectively, showing the characteristic pink color of colonies of 
Planctomycetes. 
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Table 1- Numbering given to the Planctomycetes used in this study, their affiliation, their origin of isolation, the presence 
of PKS/NRPS genes and the potential pathway product prediction (using NaPDos software).  
Strain affiliation Designation Isolate origin Bioactive genes 
 
NaPDoS 
prediction 
Aquisphaera giovannonii OJF2 Freshwater sediments PKS/NRPS ND 
Aquisphaera giovannonii OJF8 Freshwater sediments ND ND 
Rubinisphaera brasiliensis Gr7 Gracilaria bursa-pastoris PKS Myxalamid 
Rhodopirellula baltica UC21 Ulva sp. PKS ND 
Rhodopirellula baltica UC49.1 Ulva sp. PKS/NRPS Epothilone 
Rhodopirellula baltica UAP 119 Ulva sp. PKS/NRPS ND 
Rhodopirellula baltica UAP 120 Ulva sp. PKS/NRPS ND 
Rhodopirellula baltica UAP 121 Ulva sp. PKS/NRPS ND 
Rhodopirellula baltica UAP 127 Ulva sp. PKS ND 
Rhodopirellula baltica UAP 128 Ulva sp. None ND 
Rhodopirellula baltica PAP 33 Porphyra dioica PKS/NRPS ND 
Rhodopirellula baltica PAP 34 Porphyra dioica PKS/NRPS ND 
Rhodopirellula baltica PAP 61 Porphyra dioica PKS/NRPS ND 
Rhodopirellula baltica PAP 64 Porphyra dioica None ND 
Rhodopirellula baltica PAP 67 Porphyra dioica PKS ND 
Rhodopirellula baltica G1 Gelidium pulchellum ND ND 
Rhodopirellula baltica G3 Gelidium pulchellum ND ND 
Rhodopirellula baltica MsF2 Mastocarpus stellatus ND ND 
Rhodopirellula baltica Cor 1 Corallina sp. ND ND 
Rhodopirellula baltica Gtu1 Grateloupia turuturu ND ND 
Rhodopirellula baltica FF1 Fucus spirallis ND ND 
Rhodopirellula baltica FC6 Fucus spirallis ND ND 
Rhodopirellula baltica Gr17 Gracilaria bursa pastoris ND ND 
Rhodopirellula baltica SAP 113 Sargassum muticum PKS ND 
Rhodopirellula baltica SAP 114 Sargassum muticum PKS ND 
Rhodopirellula baltica SAP 115 Sargassum muticum None ND 
Rhodopirellula lusitana CcC6 Condrus crispus PKS/NRPS ND 
Rhodopirellula lusitana CcC8 Condrus crispus PKS/NRPS Pikromycin 
Rhodopirellula lusitana Sm4 Sargassum muticum PKS/NRPS ND 
Rhodopirellula lusitana UC13 Ulva sp. PKS/NRPS ND 
Rhodopirellula lusitana UC16 Ulva sp. PKS/NRPS ND 
Rhodopirellula lusitana UF6 Ulva sp. PKS/NRPS ND 
Rhodopirellula rubra UC9 Ulva sp. PKS/NRPS Bacitracin 
Rhodopirellula sp. FC 9.2 Fucus spiralis NRPS Microcystin 
Rhodopirellula sp. FF4 Fucus spiralis PKS/NRPS ND 
Roseimaritima ulvae UC8 Ulva sp. PKS/NRPS Myxothiazol 
Roseimaritima ulvae UF3 Ulva sp. PKS Stigmatellin 
ND= not determined 
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The microorganisms used as targets in the several screenings realized were a 
clinical isolate of Candida albicans, an environmental Escherichia coli and Bacillus 
subtilis ATCC 6633, from LEMUP laboratory, or Micrococcus luteus DSM 1790 and 
Chlamydia trachomatis D/UW-3/CX, from the Institute for Pharmaceutical Microbiology 
from University of Bonn. The various bioengineered Bacillus subtilis 128 reporter 
strains used in the mode of action (MoA) assay belonged also to the Institute for 
Pharmaceutical Microbiology from University of Bonn and their respective 
vectors/targets are described in Table 2. The host cells needed for maintenance of C. 
trachomatis were from the cell line Hep2, a cell line derived from the eukaryotic Human 
Epidermoid carcinoma. The adult zebrafish individuals (Danio rerio) used for 
reproduction to obtain the larvae necessary for the anti-obesity assay belonged to the 
stock of the Interdisciplinary Centre of Marine and Environmental Research from 
University of Porto, Portugal (CIIMAR) (Fig. 3).  
 
 
Table 2 - Bacillus subtilis 168 reporter strains and their respective targets of main biosynthesis pathways of the 
bacteria. 
 
 
Reporter Strain 
 
Vector 
 
Target 
B. subtilis 168 
 
pAC6-PypuA 
 
Cell Wall Synthesis 
 
pAC6-PyorB 
 
DNA Synthesis 
 
pAC6-PyheI 
 
Protein Synthesis 
 
pAC6-PyvgS 
 
RNA Synthesis 
 
 
 
 
 
 
 
 
Fig. 3- Adult zebrafish individuals from the stock of CIIMAR, in an aquarium with water settled at 25º C. 
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2. Media and other material used 
2.1. Media for maintenance and incubation of Planctomycetes  
 
For the maintenance and incubation of the freshwater Planctomycetes in pure 
culture (at 30ºC), PYGV medium was prepared (Table 3). For the incubation and 
maintenance of the marine Planctomycetes in pure culture (at 25ºC), M607 and M600 
medium were also prepared (Table 3). Both media have similar composition but M600 
has four times the concentration of the organic carbon sources. This may increase the 
production of the bioactive compounds of interest, since it creates a more stressful 
environment for the bacteria. With the objective of stimulating the production of 
bioactive molecules, other variations of the previously referred M607 medium were 
additionally prepared: M607 medium with more 15% of salt than the regular one (salt 
stress); M607 medium supplemented with 1% of an algae extract, as stimulation factor 
(M607+A); M607 medium supplemented with 1% of the previously mentioned algae 
extract plus 1% of an autoclaved culture of E.coli (M607+A+coli) and M607 medium 
supplemented with 1% of an the same algae extract plus 1% of an autoclaved culture 
of B. subtilis (M607+A+Bacillus) (both stimulation factors plus biological stress). The 
algae solution was prepared with Ulva sp., which was one of the macroalgae previously 
used for isolation of the Planctomycetes belonging to the chosen panel. Pieces of this 
macroalgae (5 grams) were macerated in sterile water and the mixture sterilized 
through a 0.22 µm filter. Another variation of M607 medium was also prepared using a 
solution of 5% of N-acetylglucosamine (NAG) instead of the glucose solution previously 
mentioned in Table 3. This compound was used in Jeske et al., 2016 to substitute 
glucose as the carbon source in the media for Planctomycetes and it was observed an 
increase in the production of bioactive molecules when complementing the media with 
it.  
The sea water that was used in the marine media was natural sea water 
collected in the north coast of Portugal. Due to the unavailability of the same natural 
water in the experiments performed during the Erasmus+ Internship in Bonn, artificial 
sea water was prepared, with small modifications of the one purposed by Lyman & 
Fleming (1940), as well as a solution using sea salts (Table 4). 
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Table 3- Composition of M607, M600 and PYGV media (Lage & Bondoso, 2011; Bondoso et al., 2011). 
 
 
Reagents 
 
Modified M13 agar medium 
(M607) 
 
Modified M14 agar medium 
(M600) 
 
     PYGV medium 
 
        Units per liter 
 
Peptone 
 
0.25 g 
 
1 g 
 
 
0.25 g 
Yeast extract 0.25 g 1 g 0.25g 
5 mM 1HCl-Tris, pH 7.5 50 mL 50 mL --------------- 
Agar 16 g 16 g 16 grams 
2Filtred natural sea 
water/3Artificial sea 
water/4Sea salts in 
deionized water 
 
900 mL 
 
880 mL 
 
--------------- 
Deionized water 10 mL --------------- 1000 mL 
5,6Glucose solution 
(2.5%) 
10 mL 40 mL 10 mL 
5,7Vitamins solution 10 mL 10 mL 10 mL 
5,8Hutner’s solution 20 mL 20 mL 20 mL 
1Tris-Hydrochloride buffer;  2 Sea water was previously filtered through a 0.45 µm pore filter;  3 Composition provided in 
Table 4; 4 Sea salts from SIGMA®; 5These components were sterilized through a 0.22 µm pore filter and added only 
after medium autoclaving; 6 The solution was prepared with sterilized water; 7 0.1 μg mL−1 cobalamine, 2.0 μg mL−1 
biotin, 5.0 μg mL−1 thiamine-HCl, 5.0 μg mL−1 Ca-pantothenate, 2.0 μg mL−1 folic acid, 5.0 μg  −1 riboflavin and 5.0 μg 
mL−1 nicotinamide; 8Cohen-Bazire et al. (1957). 
 
 
 
Table 4- Composition of artificial seawater used in the preparation of the media for marine Planctomycetes (modified from 
Lyman & Fleming, 1940). 
 
Reagents 
 
Units per liter of deionized 
water 
 
Reagents 
 
Units per liter of deionized water 
NaCl 23.477 g KCl 664.000 mg 
NaSO4 3.917 g KBr   6.000 mg 
MgCl2. 2H2O 4.981 g H3BO3 26.000 mg 
CaCl2 0.832 g SrCl2 24.000 mg 
NaHCO3  192.0 mg NaF          3.0 mg 
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2.2. Other media and organic solvents 
 
The microbial targets used for the screening assays were cultured at 37º C in 
modified Nutrient agar medium (NA medium) (Table 5), and Mueller-Hinton medium 
from Oxoid®. Mueller-Hinton agar medium was also used for preparation of the plates 
of the antimicrobial screenings with solid medium (with 1.6 % agar), including the mode 
of action assay. For diffusion assays, Mueller-Hinton soft agar medium (with only 0.6 % 
agar instead of the normal 1.6 %) was used. For the co-culture assay, Lysogeny soft 
agar medium was prepared (Table 5). Dulbecco's Modified Eagle Medium, from 
ThermoFisher Scienthific, was the medium in which the previously available 
suspension of Hep2 cells (used as host cells for the chlamydial assay) were cultured. 
This media was also previously complemented with 5 mL/L of three solutions prepared 
specifically for this medium, also from ThermoFisher Scienthific: vitamins, fungizone 
and non-essential aminoacids. Additionality, 50 µg/ml gentamycin and 10% heat 
inactivated fetal calf serum supplemented the medium. For the maintenance of the 
zebrafish larvae in petri-dishes, one solution, designed as egg water, was prepared, 
consisting in Instant Ocean® Sea Salts dissolved in distilled water at a final 
concentration of 60 µg/ml.  
 
  Table 5- Composition of Nutrient agar medium (NA medium) and Lysogeny soft agar medium. 
 
Reagents 
Nutrient agar medium 
 
Units per liter  
Lysogeny soft agar medium 
 
 Units per liter 
 
Peptone 
 
5 g 
 
-------------- 
 
Yeast extract 
 
1 g 
 
5 g 
 
Agar 
 
16 g 
 
6 g 
 
Tryptone 
-------------  
10 g 
 
NaCl 
--------------  
10 g 
 
Deionized water 
 
1000 mL 
 
1000 mL 
 
Organic solvents used for extraction of compounds and to dissolve extracts 
were ethyl acetate from PanReac AppliChem and VWR®; acetone from VWR®; 
dichloromethane from MERCK, dimethyl sulfoxide (DMSO) from VWR® and methanol 
from MERCK. 
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3. Extraction of compounds for small scale studies 
 
In order to evaluate antimicrobial activity by the potential compounds synthetized 
by Planctomycetes, the first step was to extract in small scale those possible metabolites 
produced for further screening. After normal incubation in M607 agar plates, marine 
strains were then incubated for 7 days in 20mL of several of the liquid variations of 
media exposed in section (2.1), at 25ºC and 220 rpm. Each culture was then used to 
prepare four different types of extracts of compounds: three organic (from the cell pellet 
(P), from the supernatant of the culture (S) and from the crude culture (C)) and one 
aqueous, from the filtrate of the culture (F). For the aqueous extract, 2mL of culture were 
centrifuged at 13.300 rpm. The supernatant was then sterilized thought a 0.22 µm filter. 
For the organic extracts, an organic mixture consisting in 90% acetone plus 10% DMSO 
was prepared. To prepare the crude extract, 2mL of the organic mixture were mixed with 
2mL of the culture for 1 hour under continuous shaking, at 25ºC. For the pellet and the 
supernatant extracts, 2mL of culture were centrifuged at 13.300 rpm for 5 minutes and 
the supernatant and the pellet collected. To each, 2mL of the organic mixture was added 
followed by incubation for one hour under continuous shaking at 25ºC. After incubation, 
2mL of the upper phase of the three organic extracts (P, S and C) were passed to new 
tubes and dried to about half of the volume (during 12 hours). The respective volumes of 
the P extracts were then completed until 2 mL using sterile water. All extracts obtained 
were then stored at -20ºC until use.  
 
4. Extraction of compounds for up-scaled studies  
4.1. Liquid-liquid extraction with ethyl acetate  
 
The secondary metabolite production in natural environments is normally very 
low and subsequently the resultant concentration of products of interest very scarce 
within the extracted mixture, since more compounds besides the ones pretended are 
also present at the same time. Based on this fact, an up-scaling of the cultures was 
made in order to enhance the amount of metabolites with interest. Several of the 
marine strains were therefore incubated in 500 mL of regular medium M607, for 7 days 
at 25ºC under continuous shaking (Fig. 4). One of the strains (strain MsF2) was also 
selected for incubation in 500 mL of two medium variations (see section 2.1): M607 
FCUP 
Exploring the secondary metabolite potential of Planctomycetes from marine and freshwater environments 
31 
 
 
medium supplemented with 1% of a solution of an autoclaved culture of B. subtilis plus 
1% of algae extract and M607 medium only supplemented with 1% of the same algae 
extract. The two strains from freshwater environments (OJF2 and OJF8) were 
incubated in 1L of PYGV medium for 12 days at 30ºC under continuous shaking.  
 
 
 
 
 
 
 
 
 
 
 
 
Ethyl acetate is a powerful organic solvent and it was used to extract possible 
compounds of interest produced from the obtained up-scaled cultures. Therefore, after 
the incubation period of the strains, ethyl acetate was added to the cultures at double 
of their amount in a separation funnel (Fig. 5A). Since ethyl acetate is not miscible with 
water (Fig. 5B), two different liquid phases in the mixture were formed. The lower 
phase was discarded and the upper phase (correspondent to an organic phase with 
ethyl acetate and possible compounds extracted) transferred to a balloon to be 
subsequently dried in a rotatory vacuum evaporator (Rotavapor® R-100 equipment 
from BUCHI). With temperature settled around 30ºC, pressure established around 100 
millibar and rotation, ethyl acetate was completely removed by evaporation and 2 mL of 
DMSO were used to dissolve the solid residues achieved (Fig. 5C). The resultant 
extracts were then stored at -20º C until use.  
 
 
Fig. 4- Cultures of strain MsF2 in regular M607 medium ready for extraction, after 7 days incubating at 25ºC under 
constant shaking.   
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4.2. Extraction with methanol  
  
Another protocol for culturing and extraction of Planctomycetes was assayed. In 
order to enlarge even more the volume of culture used, 2L of medium M607 were used 
to incubate strain MsF2 during 7 days under constant shaking. After this period, cells 
were collected by centrifugation at 3600 rpm for 5 minutes, in an Eppendorf™ 5810R 
Centrifuge. To investigate a new type of extraction, methanol was the selected solvent, 
chosen by its common use for this purpose of extraction of bioactive molecules (Leão 
et al., 2013). This extraction, which was performed at collaboration with CIIMAR, 
consisted in subjecting the previously pelleted cells to numerous periods (30 minutes 
each) of incubation with the referred methanol (Fig. 6A). Pellet was then collected, 
leaving methanol with possible compounds extracted (Fig. 6B). The mixture was 
subsequently evaporated in a rotatory vacuum evaporator, with temperature settled 
around 30 ºC, pressure in 100 millibar and rotation. Two mL of methanol were used to 
dissolve the extract obtained and subsequently transferred to a glass vial. The mixture 
was then subjected again to evaporation in a rotatory vacuum evaporator under the 
same conditions and to a final drying in a freeze dryer (Telstar® equipment) (Fig. 6C). 
Fig. 5- Sequential phases of strain MsF2 crude extraction with ethyl acetate: A= beginning of the extraction; B= two 
final different liquid phases clearly distinguish (upper phase= ethyl acetate, lower phase=rest of the culture); C= 
resultant extract obtained after drying in a rotatory vacuum evaporator, dissolved in 2mL of DMSO. 
A B C 
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Lastly, the extract was dissolved in 2 mL of DMSO plus 1 mL of methanol and stored at 
-20º C until use. 
 
 
 
 
 
 
 
 
 
  
 
 
 
4.3. Incubation of cultures using XAD resin and extraction with ethyl 
acetate and acetone 
 
More protocols were tested for incubation and extraction of metabolites from 
Planctomycetes. A special resin was used to allow the accumulation and further 
extraction of compounds possible present in the aqueous phase of the cultures. Resin 
Amberlite® XAD16N (Fig. 7A), from MERCK, is specifically designed to adsorb and 
hold hydrophobic compounds up to 40,000 MW, being antibiotics the ones with more 
interest for this thesis. At the same time, another up-scaling was intended. Thus, a 3L 
culture of strain MsF2 was prepared using medium M607 and incubated for 7 days at 
25ºC under continuous shaking. At late of the exponential growth phase (around day 3) 
1.5 g/100 mL of resin was added to the cultures (Fig. 7B and C). At the end of the 
incubation, the resin was separated from the rest of the culture.  
A 
B 
Fig. 6- Extraction of MsF2 cell pellet with methanol: A= incubation with methanol of the pellet obtained from 
centrifugation of the 2L culture of strain Msf2 in M607 medium; B= Methanol extract after filtration of the previous 
referred pellet; C= Resultant dried extract. 
B C 
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For secondary metabolite extraction, 270 mL of ethyl acetate were added to the 
resin and incubated for 1.5 h. The extracted resin was again collected and stored for 
further use. Ethyl acetate was evaporated in a rotatory vacuum evaporator with 
pressure settled around 100 millibar, temperature around 30ºC and rotation. The solid 
residue obtained was dissolved in 5 mL of methanol and stored at -20ºC until use. 
The same resin was after used for a second extraction, this time with acetone. 
This protocol was based on a recent study where the presence of bioactive compounds 
was demonstrated in Planctomycetes using the same methodology (Jeske et al., 
2016). Therefore, 750 mL of acetone were added to the resin and incubated 1.5h. The 
resin was collected and the solvent was removed by evaporation in a rotatory vacuum 
evaporator with temperature settled around 30º C, pressure around 100 millibar and 
rotation. Eight mL of methanol were then used to dissolve the residues achieve. The 
culture (that remained after filtration of the resin) was also subjected to extraction. 
Thus, the 3L of culture were divided in 50mL falcons and centrifuged at 3600 rpm for 5 
minutes. The cell pellets were then collected (Fig. 8A) and subjected to extraction with 
100mL of ethyl acetate for 1h, under continuous shaking (Fig. 8B). The mixture was 
dried in a rotatory vacuum evaporator with temperature settled around 30ºC, pressure 
in 100 millibar and rotation. The residue obtained was dissolved in 2mL of methanol 
(Fig. 8C). The extracts obtained from these various extraction techniques were 
subsequently screened for bioactivity. 
Fig. 7- Incubation of strain MsF2 with resin: A= falcon with the chosen resin XAD16N; B and C= cultures of strain MsF2 
in M607 medium incubating with the referred resin.  
A B C 
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5. Screening assays 
5.1. Bioactivity assay in liquid medium 
 
To firstly check if any of the extracts of Planctomycetes obtained from small 
scaled cultures (section 3) had any effect on the growth of a panel of pathogens, a 
bioactivity assay in liquid medium, carried out as described by Graça et al., (2015; 2016) 
with small modifications, was made. The targets used were chosen as representatives of 
the main groups of interest: Bacillus subtilis for Gram-positive bacteria, Escherichia coli 
for Gram-negative bacteria and Candida albicans for fungi. The cultures used were 
prepared according to the following procedures: they were incubated overnight in 
Nutrient broth at 37ºC under continuous shaking (220 rpm). The absorbance of the 
cultures was measured at 600 nm and the cell concentration adjusted to 2.5 × 105 
CFU/mL, as described in more detail in the next paragraph.   
 To adjust the cell concentration of each target (with the objective of 
standardized the concentration used), 3 growth curves for each pathogen were initially 
performed. They were incubated overnight (OV) at 37ºC in Nutrient broth, with 
continuous shaking. Then, the initial absorbance at 600 nm was measure and the 
B 
Fig. 8- Collection and extraction of MsF2 cell pellet with ethyl acetate: A= cell pellet collected after centrifugation of the 
3L culture of strain MsF2 in M607 medium; B= organic extraction of the referred pellet with ethyl acetate; C= final 
extract obtained, dissolved in 2mL methanol.  
A B B C 
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process was repeated every 30 minutes until the microorganisms entered the 
stationary phase. In parallel, at every 30 minutes, each culture was used to make serial 
dilutions (with sterile water) with a factor of ten (from 10-2 - 10-8) and 3 drops of 10 µL of 
each dilution were inoculated in Nutrient agar. The cultures were incubated for 24h at 
37 ºC and the colony forming units (CFUs) were then counted. The analysis of the 
results consisted in the graphic representation of logarithmic data of absorbance or 
CFUs according to time and delimitation of exponential phase with subsequent 
determination of the correspondent equation and time of duplication. With the 
information given by this equation, the concentration of the cultures of the three targets 
was adjusted for the one that was pretended based on the optical density measured 
right before use. 
The bioactivity assay in liquid medium was performed in 96 well-plates with flat 
bottom from Orange ScientificTM (Fig. 9). For each extract (assayed in triplicate), 10 µL 
were incubated with 90 µL of each standardized target culture in the respective well in 
the plate. Each target was also preferentially assayed in separate plates. Also in 
triplicate, four different positive controls for each target were used, in which 10 µL 
together with 90µL of the respective pathogen were incubated: for Candida albicans, the 
positive controls were four concentrations of amphotericin B (0.19 µg.mL-1; 0.39 µg.mL-1; 
0.78 µg.mL-1 and 1.56 µg.mL-1), for Bacillus subtilis, four concentrations of 
chloramphenicol (3.75 µg.mL-1, 7.5 µg.mL-1, 15 µg.mL-1 and 30 µg.mL-1) and for 
Escherichia coli, four concentrations of rifampicin (62.5 µg.mL-1, 125 µg.mL-1, 250 µg.mL-
1 and 500 µg.mL-1). The three negative controls, also in triplicate, were as follow: 100 µL 
of Nutrient broth; 100 µL of each target culture and 10 µL of M607 liquid medium plus 
90µL of each target culture. Initial absorbance measurement was performed at 600 nm 
in a Multiskan GO plate reader from Thermo ScientificTM and the plates were then 
incubated for 24 hours under continuous shaking at 37ºC. After the incubation period, a 
final absorbance measurement was also performed. Analysis of the results consisted in 
the calculation of the percentage of inhibition of the growth of the targets for which well, 
based in the optical density values obtained, using the following equations: 
 
𝑂𝐷𝑅 = 𝐴𝑏𝑠𝐹 − 𝐴𝑏𝑠𝐼 
In which ODR= Optical density of each replica; Absf= Final absorbance after 24h; 
AbsI= Initial absorbance at 0h. 
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Fig. 9- Example of a 96-well plate used in the bioactivity liquid assay, already filled with 10µL of the extracts of 
Planctomycetes/controls plus 90µL of standardized culture of B. subtilis in NA broth medium, before incubation.  
𝑂𝐷𝐸𝑥𝑡 =
𝑂𝐷𝑅1 + 𝑂𝐷𝑅2 + 𝑂𝐷𝑅3
3
 
ODExt= Optical density of each extract (media of the triplicates). 
%Inhibition for each extract = 100 −
𝑂𝐷𝐸𝑥𝑡
𝑂𝐷𝐶
∗ 100 
Where ODc= optical density of the control M607 medium + target culture, after 24h. 
Inhibitory values above 20 % were considered as bioactive and having an effect in 
the growth of the targets. 
 
 
 
 
 
 
 
 
 
 
 
 
5.2. Modified Kirby-Bauer assay 
 
To complement the previously described bioactivity assay in liquid medium (96-
well plate assay) and to serve as the main antimicrobial screening in this thesis, a 
protocol with small modifications to the commonly used Kirby-Bauer assay was 
prepared and followed. 
The targets chosen to be tested against in this assay were Micrococcus luteus 
and Bacillus subtilis, since they are sensitive and easy bacteria to detect antimicrobial 
activity. Firstly, an OV culture of each target was made in Mueller-Hinton liquid 
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medium, at 37º C under continuous shaking.  The OD at 600nm was then measured 
and the exact amount of culture to use (to allow a standardize concentration of 0.5 
McFarland) determined using the following formula:  
 
Amount of culture to seed =  
Total volume of mixture to seed in each plate [mL] ∗ 107
OD600nm ∗ (2 ∗ 109)
 
 
The culture was then subsequently incorporated in Mueller-Hinton agar medium 
and the mixture spread in rectangular NuncTM OmniTrayTM plates, squared petri dishes 
or regular round petri ones (for the bigger plates, 40 mL of the mixture were spread and 
for the normal round petri dishes, 20 mL). With adequate space in between, drops of 
extracts of Planctomycetes with 10 to 50 µL were poured into the surface of the agar 
(Fig. 10), following incubation of target cultures at 37º C. After 24h, inhibition halos 
were searched for in the spot of where the extracts were inoculated. The positive 
control for an example of inhibition was a drop of 10 µL of 0.1 µg/mL ampicillin or 
1mg/mL ampicillin. At the same quantity of the extracts, the negative control that was 
used in each plate variated accordingly to the solvent in which every type of extract 
was dissolved (DMSO or methanol).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 10- Example of a NuncTM OmniTrayTM plate used in the modified Kirby-Bauer assay, filled with 40 mL of a 
standardized culture of B. subtilis incorporated in Mueller-Hinton agar. Blue dots correspond to the local were a drop of 
an extract was placed.  
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5.3 Well assay  
 
Since the lastly described assay only permitted the use of, in maximum, 50 µL 
of each extract, another protocol was also used for the screening of antimicrobial 
activity, with the intent to enlarge the quantity of extract tested. This well assay has 
similarities with the modified Kirby-Bauer assay, where Mueller-Hinton agar plates were 
also incorporated with a standardized culture of B. subtilis or M. luteus (see section 
5.2). On the other hand, instead of drops of extracts inoculated into the surface of the 
plate, wells were made directly into the agar and filled with 100 µL of each extract. 
Positive controls for an example of inhibition were 10 µL of 0.1µg/mL ampicillin and 
1mg/mL ampicillin. At the quantity of 100 µL, the negative control that was used in each 
plate variated accordingly to the solvent in which every type of extract was dissolved 
(DMSO or methanol). The cultures were incubated at 37º C for 24h and inhibition halos 
were searched for near the wells.  
 
5.4 Diffusion assay with filter discs  
 
 In order to prevent evaporation or diffusion complications by the compounds 
possibly present in the extracts that may occur in normal Mueller-Hinton agar cultures 
(which were used in the two screenings immediately described) a diffusion assay with 
filter discs was also used to test the antimicrobial activity of extracts of Planctomycetes. 
Similarly with the last screenings, OV cultures of B. subtilis and M. luteus were 
prepared and their concentration standardized (see section 5.2). Two layer plates were 
then organized: a first layer constituted by regular Mueller-Hinton medium (with 1.6 % 
agar) and a second layer of Mueller-Hinton soft agar medium (with 0.6 % agar) 
incorporated with the standardized target culture. Previously sterilized filter discs were 
then placed above the surface of the agar and filled with 50 or 100µL of each extract. 
The positive control used to show inhibition was a filter disc filled with 10µL of 1 mg/mL. 
Solvent controls were filter discs also filled with 50 or 100 µL of the solvent used to 
dissolve the respective extracts. Cultures were incubated at 37 ºC for 24h and 
inhibition halos were searched for near the discs.  
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5.5. Co-culture assay 
 
To observe if live cultures of Planctomycetes were producing bioactive 
compounds that inhibit the growth of the targets, a co-culture assay was performed. 
Firstly, Planctomycetes were incubated for 3 days in M607 plates, at 25ºC. An OV 
culture of M. luteus was made in Mueller-Hinton liquid medium, at 37ºC, and the 
concentration standardized (see section 5.2). This culture was then incorporated in 
Lysogeny soft agar medium and the mixture poured above the surface of the agar 
plates with live cultures of Planctomycetes. These cultures were then incubated for 24h 
at 30ºC. Inhibition of the growth of the colonies of M. luteus was searched for near the 
colonies of Planctomycetes. 
 
5.6. Evaluation of anti-Chlamydia trachomatis activity using a 
fluorescence-microscopy based assay 
 
 With the collaboration of Dr. Anna Klöckner in the Institute for Pharmaceutical 
Microbiology of University of Bonn, it was possible to test the antimicrobial activity of 
some of the extracts achieved against Chlamydia trachomatis, a pathogenic species 
from phylum Chlamydiae. Having in mind that Chlamydiae belong to the same super-
phylum as Planctomycetes and that the usual bioactive producers are from other 
phylogenetical branches, it was of interest to see if molecules produced by 
Planctomycetes had any effect in the growth of this pathogen, besides the firstly used 
targets. On the other hand, chlamydial infections are also a concern, mostly in sub-
developed countries. Its difficulty of treatment by its intracellular activity and the 
appearance of resistant strains make it necessary to search for new antibiotics.  
 Firstly, 200 µL of an available suspension of host cells (needed for chlamydial 
maintenance) from eukaryotic line Hep2 (previously grown in complemented 
Dulbecco’s Modified Eagle medium (see section 2.2)) were collected and incubated in 
96-well plates for 48h. Then, 50 µL of the supernatant of an available preparation of 
Chlamydia trachomatis D/UW-3/CX (mixed at 1:1 in Saccharose-phosphate-glutamate 
(SPG) buffer (75 g/L sucrose, 0.52 g/L KH2PO4, 1.53 g/L Na2HPO4 and 0.72 
glutamate)) were added to the host cells, with 1.2 µg/ml cycloheximid. Cycloheximid is 
an inhibitor of protein biosynthesis in eukaryotic cells and was used to support the 
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chlamydial infection, which occurred for 48 h at 37 °C with 5 % of carbon dioxide (CO2). 
Medium was then removed and renewed with 100 µL of fresh one and the cells 
exposed to several different treatments: extracts of Planctomycetes dissolved in DMSO 
within two amounts (2.56 µL and 1.28 µL diluted in 1.28 µL of sterile water), DMSO 
(also 2.56 µL and 1.28 µL diluted in 1.28 µL of sterile water) and 1µg/mL of the 
antibiotic ciprofloxacin. Cultures were then incubated for 30 h at 37 °C with 5 % CO2 
and successively fixed with ice cold methanol for 5 min. To evaluate the effects of 
these treatments in the chlamydial growth, samples were stained using fluorescein-
conjugated antibodies specific for chlamydial lipopolysaccharides (LPS): Pathfinder 
Chlamydia Conformation System kit (from Bio-Rad, Germany) was diluted 1:5 with 
phosphate buffered saline (PBS) from ThermoFisher Scienthific and 100 µL were 
added to each well and incubated for 30 min at 37 °C. Evans' blue is a dye that 
additionally stains the host cell cytoplasm and it was already included in the lastly 
referred kit. For an extra staining of the host cell DNA, samples were also incubated for 
1 min with 3 mg/mL of the fluorescent stain DAPI (4',6-diamidino-2-phenylindole) 
followed by 2 washing steps with PBS with 10 min each. The samples were then 
analyzed by fluorescence microscopy. For comparison, more two controls were 
prepared for this assay:  infected cells with no treatments and non-infected cells.   
 
5.7. Mode of action assay 
 
 To search for the cellular target of the compounds from Planctomycetes 
extracts, a mode of action assay was performed. Antibiotics generally function by 
disturbing the important biosynthetic pathways in bacteria. The type of pathway that is 
affected is determined by their mode of action. Previously genetically engineered 
strains of Bacillus subtilis 128 (designated as reporter strains) were transformed with 
pAC6-vector promotor fusions, each one containing one promotor specific for each 
main biosynthesis pathways in bacteria: cell wall biosynthesis= PypuA, DNA 
biosynthesis= PyorB, protein biosynthesis= PyheI and RNA biosynthesis= PyvgS 
(Urban et al., 2007). To evaluate if an extract has effects in one of these pathways, a 
LacZ gene copy was also added to the vector. This gene encodes for β-Galactosidase, 
which, in the presence of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) is 
hydrolyzed into two compounds: galactose and the dye 5,5'-dibromine-4,4'-dichlorine, 
characterized by its deep blue color. As so, if any pathway is stressed by a compound, 
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the promotor is activated and the LacZ gene transcribed. The formation of the blue 
residue is the confirmation of this activation (Urban et al., 2007). To perform this assay, 
each reporter strain was incubated OV in liquid Mueller-Hinton complemented with 5 
µg/mL chloramphenicol. Then, the concentration of the culture was standardized (see 
section 5.2) and incorporated in Mueller-Hinton agar, with an extra supplement of 5 
µg/mL chloramphenicol and X-Gal (88 µg/mL for DNA, protein and RNA targets and 44 
µg/mL for cell wall target). These mixtures were then spread in rectangular plates and 
drops of 50 µL of extracts from Planctomycetes placed above the surface of the agar, 
with adequate space in between. At the concentration of 500 µg/mL, four different 
types of controls were used to show an example of activation of each biosynthetic 
pathway: ampicillin for cell wall, tetracycline for protein synthesis, rifampicin for RNA 
and vancomycin for DNA. The cultures were then incubated for 24h at 37ºC. In the 
end, inhibition halos were searched for in the extracts spots, as well as the visualization 
of blue color around them (Fig. 11).  
 
 
 
 
 
 
 
 
 
 
  
Fig. 11- Mode of action assay with Bacillus subtilis 128 transformed with pAC6-vector containing the promotor PyheI 
(for protein target), with an example of the respective promotor activation by 500 µg/mL tetracycline, as visualized by 
the appearance of blue color around the inhibition halo (arrow).  
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5.8. Anti-obesity assay using zebrafish larvae with Nile red staining 
 
 In collaboration with CIIMAR, it was possible to test extracts from 
Planctomycetes against other types of aims, such as the production/accumulation of 
lipids, using larvae of zebrafish as model organism. Unpublished studies with some of 
the same strains of Planctomycetes have showed that extracts of these bacteria have 
cytotoxic effects against different cancer cells types. Having this activity, the 
metabolites produced by these bacteria can possibly affect other targets inside the 
eukaryotic cells, such as the production of lipids.  Zebrafish larvae were the chosen 
organism as a model for live evaluation of anti-obesogenic activity because of the 
facility of manipulation and easy visualization of the results, since it is possible to 
induce transparence into these larvae by adding a solution of phenylthiocarbamide 
(PTU), which inhibits the melanogenesis, reducing at the same time the necessity of 
mammalian studies (Noinart et al., 2017 and Tingaud-Sequeira et al., 2011). Zebrafish 
larvae also respond to known lipid regulator drugs similarly as humans (Jones et al, 
2008). 
 Specifically for this assay, new extracts were obtained. Firstly, medium sized 
cultures (100mL) were prepared for 9 chosen strains of marine Planctomycetes (UC16, 
UC9, Rb, CcC6, MsF2, FF1, Gr7, UC 49.1 and UC13) in medium M607 and incubated 
for 7 days at 25ºC under continuous shaking. These cultures were then used for 
compounds extracting using ethyl acetate, following the protocol in section (4.1). The 
solid residues obtained were dissolved in 3 mL of dichloromethane, transferred to glass 
vials and left under evaporation for one day. The dry weight of the extracts was then 
calculated and standardized solutions with a concentration of 10 mg/mL were prepared 
with DMSO and stored at -20º C. For the obtainment of the larvae of zebrafish 
necessary for this assay, 10 adult males and 10 adult females belonging to Danio rerio 
species were firstly selected by their size (bigger individuals were preferred) and 
transferred to an aquarium prepared specifically for the reproduction and further 
collection of eggs (Fig 12A).  One day after, eggs were available for harvest. They were 
firstly cleaned from the debris and fezzes (Fig. 12B) and then left for hatching in an 
aquarium with water at 25º C. After 72h, larvae were collected to petri dishes with egg 
water (see section 2.2) (Fig. 12C). They were then sorted by size and transferred in 
groups of 7 per well to a 48-well plate, along with some egg water (Fig. 13).   
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 For the beginning of the exposure to different treatments, in each well, the egg 
water was firstly withdrawn with a syringe and renewed by 625 µL of a solution of egg 
water supplemented with 200 µM phenylthiocarbamide (PTU). The several treatments 
were then added to the respective wells: 0.75 µL of Planctomycetes extracts, 0.75 µL 
of the solvent/negative control DMSO and 0.75 µL of a previously prepared solution of 
11.412 mg/mL resveratrol (positive control to show lipid inhibition) dissolved in DMSO 
(Fig. 13). After 24h of exposure, the mixture in each well was again renewed 
accordingly to the amounts previously described. Fifteen microliters of a 500 mg/mL 
solution of Nile red dissolved in acetone were also added to each well, to allow a 
fluorescent staining of both membrane and intracellular neutral lipids. After a final 
Fig. 12- Obtainment of larvae of zebrafish for use in the anti-lipid production assay: A= Aquarium used for adult 
zebrafish reproduction. Ten females and ten males were previously selected by their size (bigger individuals were 
preferred). Temperature of the water was settled at 25ª C; B= Eggs harvested after reproduction; C= Hatched larvae 
after 72h incubation of the eggs at 25º C. 
A 
B C 
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incubation of more 24h, larvae were anesthetized with 3 to 4 drops of a solution of 0.3 
% tricaine and the larvae of each well transferred to concave slides in groups of three 
or four. The fluorescence of Nile Red was induced in a Leica DM6000 microscope 
(excitation wavelength of 515-560 nm) and images of the larvae and fat accumulation 
were obtained, to subsequent analysis and calculation of the intensity of fluoresce 
using the software ImageJ. The mean level of fluorescence intensity obtained for all 
larvae exposed to the negative control (DMSO) was considered as 100 % lipid 
production/accumulation and so taken as 0 % activity of lipid production inhibition. The 
mean percentage of inhibition of lipid production was then calculated for each 
treatment, using this control to comparison. All data obtained from the ImageJ analyzes 
to all larvae was also statistically treated using an one-way analysis of variance 
(ANOVA) test done in Microsoft® Office Excel, with alpha level set at 0.5. Dunnett’s test 
was also performed to evaluate statistic differences between each treatment and the 
control. 
 
 
 
 
 
 
 
 
 
 
 
6. Gel permeation chromatography 
  
 In order to begin the isolation of the compound/s of interest from the screened 
heterogeneous extracts obtained from the cultures of Planctomycetes, gel permeation 
Fig. 13 - 48-well plate prepared for the anti-obesity assay, in the beginning of the exposure: in each well, 7 larvae 
were initially placed, as well as 625 µL of egg water + 200 µM PTU and 0.75 µL of 10 mg/ml extracts from 
Planctomycetes. 
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chromatography was the technique chosen because it allows the separation of the 
existing components in mixtures by their molecular size into different fractions. 
 A fresh culture of strain Gr7 was prepared in 500mL of medium M607 
complemented with 1% of algae extract. After 7 days incubation at 25ºC under 
continuous shaking, this culture was extracted with ethyl acetate, as described in 
section (4.1). At the end, the solid residue achieved was dissolved in 2mL of methanol, 
since this is the solvent used in the chromatography. In collaboration with the 
Department of Chemistry from Sciences Faculty of Porto University, gel permeation 
chromatography was performed to the obtained extract in a device with a GILSON® 
pump and a Sephadex LH20 column, chosen by its normal use to separate terpenoids 
and small weight peptides. This column was previously stabilized overnight with 
methanol before use. With 2mL of the extract injected into the column at the velocity of 
separation of 1 mL/minute, fractions were collected every 15 minutes, from minute 0 to 
minute 225 (Fig. 14). Then, every fraction was dried in a rotatory vacuum evaporator, 
with temperature settled around 30ºC, pressure in 100 millibar and rotation. The 
residues obtained from each fraction were dissolved in 2mL methanol and the 
antimicrobial activity evaluated. The final objective was the search for inhibition halos 
after 24h of incubation at 37ºC, to see if and which fractions were bioactive to be 
chosen for further fractioning (aiming at a final isolation of the compound).  
 
 
 
  
Fig. 14- Collection of fractions obtained from gel permeation chromatography of strain Gr7 extract (from 500mL 
culture in medium M607+A). 
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Results  
 
1. Small scale studies  
1.1. Preliminary screenings 
  
 To achieve assays reproducibility, the preliminary antimicrobial screening 
performed was based on a certain and constant level of the target strains. 
Consequently, the growth of the three selected targets (B. subtilis, E. coli and C. 
albicans) was firstly studied and the time of duplication of each strain calculated. The 
duplication times obtained were 30.12 minutes for B. subtilis, 49.35 minutes for E. coli 
and 78.92 minutes for C. albicans. The relationship between the absorbance reads at 
600 nm and the CFUs were also calculated and used for each target culture to 
standardize its concentration, according to the following equations: 
 
For 𝐵. 𝑠𝑢𝑏𝑡𝑖𝑙𝑖𝑠: ln (𝐶𝐹𝑈𝑠) =  
0.0251 ln(𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑎𝑏𝑠 600𝑛𝑚) + 0.2210
0.031
+ 7.4049  
 
For 𝐸. 𝑐𝑜𝑙𝑖: ln (𝐶𝐹𝑈𝑠) =  
0.0121 ln(𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑎𝑏𝑠 600𝑛𝑚) + 0.0449 
0.013
+ 12.152  
 
For 𝐶. 𝑎𝑙𝑏𝑖𝑐𝑎𝑛𝑠: ln (𝐶𝐹𝑈𝑠) =  
0.0112 ln(𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑎𝑏𝑠 600𝑛𝑚) + 0.0316 
0.004
+ 7.601  
 
In the preliminary 96-well plate screening of 12 marine Planctomycetes 
(UAP119, UAP120, UAP121, UAP127, UAP128, PAP33, PAP34, PAP61, PAP64, 
PAP67, SAP113 and SAP114), the majority of the 10 µL DMSO+acetone extracts 
(obtained from 2 mL of cultures) (see section 3 from the methodology) showed to 
induce inhibition against B. subtilis (Fig. 15). Only inhibitions higher than 20% were 
considered. Although all inhibitions were lower than the positive control of 30 µg/mL 
chloramphenicol (82 %) several values higher than 60 % were obtained. In general, the 
most effective extracts were the ones from the cell pellets (mean inhibition values of all 
extracts = 65 %), followed by the extract from the supernatant (mean value of 48 %). 
The crude extracts were the ones showing lower inhibitory effects. Strains SAP113 and 
UAP127 where the ones with extracts that surpass 70 % inhibition. These results 
indicated that the higher bioactivity was obtained in organic extracts, especially from 
the cells. The aqueous extracts (F), although all bioactive with levels higher than 30 % 
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(with the exception of SAP114) were lower than the organic ones (S and P). Why the 
crude extract was lower than all the others is behind comprehension. These results are 
consistent with the results obtained by Graça et al. (2016), where other marine 
Planctomycetes were screening with this kind of assay. However, no bioactivity was 
observed for any extract against the other two targets, the fungus C. albicans and the 
resistant E. coli. Graça et al (2016) observed bioactivity against C. albicans, but also 
not against E. coli. 
 In a similar assay with the same strains but performed with extracts from 
cultures using medium M600, measurement of bioactivity was impossible because the 
negative control (target culture exposed only to medium M600) showed inhibitory effect 
on the targets growth. This fact is unfortunate, as the higher levels of bioactivity 
obtained by Graça et al., (2016) were in extracts obtained from medium M600.  
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Fig. 15- Inhibition levels of B. subtilis after exposure to different extracts of Planctomycetes: A- treatment with the 
extracts obtained from the supernatant (S) and pellet (P) of centrifuged cultures. B- treatment with the extracts obtained 
from filtrated cultures (F) and crude cultures (C). 30 μg/mL chloramphenicol (CAM) was the positive control. The levels 
of inhibition are the ones obtained relative to B. subtilis exposed to M607 medium (0% inhibition). Almost all extracts 
showed inhibition against this target above 20 %, with some reaching more than 60 %, although none as the 
chloramphenicol positive control.   
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 To complement the previous preliminary screening, a modified Kirby-Bauer 
assay was performed at the beginning of the internship in Bonn, with an enlarged 
number of marine Planctomycetes (35 strains) (Table 1) that allowed the screening of a 
higher diversity. However, the medium M607 for strain cultivation was prepared with 
artificial sea water, due to the unavailability of natural one. The target strains were B. 
subtilis and M. luteus and were also standardized to a similar concentration, for assay 
reproducibility. In the screening against M. luteus with the 10 µL droplets of the 
DMSO+acetone extract (obtained from 2 mL of cultures), two of them (pellet extracts 
from strains FF1 and MsF2) showed a slight inhibition halo (Fig. 16). However, against 
B. subtilis no inhibition halo was observed for any extract (Fig. 17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16– Modified Kirby-Bauer assay with small-scale extracts of Planctomycetes tested against M. luteus, after 24h 
incubation at 37º C. A= two inhibition halos were visualized for Pellet extract from both strains FF1 and MsF2. B= referred 
inhibition halos in more detail.  
A 
B 
Pellet 
FF1 
Pellet 
MsF2 
Pellet 
FF1 
Pellet 
MsF2 
Fig. 17 – Modified Kirby-Bauer assay with small scale extracts of Planctomycetes tested against B. subtilis, after 24h 
incubation at 37º C. The control was 10 µL of 1µg/mL ampicillin (C). No inhibition halos were observed for any extract. 
C 
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 The preliminary antimicrobial screening with the modified Kirby-Bauer assay 
confirmed, although weakly, the previous referred potential of marine Planctomycetes 
to produce bioactive compounds (the 96-well assay and the data from the literature 
(Graça et al., 2016)). Therefore, an optimization was required in order to potentiate the 
bacterial inhibitory capacity.  
 
1.2. Optimization of incubation conditions: organic stress, biological 
stress, natural environment simulation, chemical stress and NAG as 
carbon source 
 
 Still in a small scale, various modifications to the media used for incubation of 
the marine planctomycetes with the objective to optimize the production of bioactive 
compounds were performed. To induce organic stress, strains were incubated in 20mL 
of medium M600 (which as a 4x fold the organic sources concentration of medium 
M607). Extraction with DMSO+acetone was made to 2 mL of the 20 mL cultures (see 
section 3 from the methodology) and the screening was made with the modified Kirby-
Bauer assay against M. luteus, with 10 µL droplets of extract. However, no inhibition 
halos were observed for any of the extracts (Fig. 18). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18– Modified Kirby-Bauer assay with small scale extracts of Planctomycetes (from M600 cultures) tested against 
M. luteus after 24h incubation at 37º C. The control was 10 µL of 1µg/mL ampicillin (C).No inhibition halos were 
observed for any extract.  
C 
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To induce biological stress and to simulate competitive natural environmental 
conditions, fresh cultures of the marine Planctomycetes were prepared in M607 
medium supplemented with 1% of an autoclaved culture of E. coli and 1% of a solution 
of algae extract. These cultures were then extracted and screened in the same way 
(see sections 3 and 5.2, respectively, from the methodology), against B. subtilis and M. 
luteus, using 10 µL drops of extract. However, no inhibition halos were, again, 
visualized for any extract (Fig. 19). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
To simulate salt stress (chemical stress), fresh cultures of the marine 
Planctomycetes were incubated in medium M607 with higher percentage of salt (an 
increase of 15 %). For comparison, all marine strains were also cultured in the normal 
medium M607. The extracts were obtained following the same protocol, with 2 mL 
Fig. 19 – Modified Kirby-Bauer assay with extracts of Planctomycetes (from biologically stressed cultures) tested 
against B. subtilis (A) and M. luteus (B), after 24h incubation at 37ºC. The control was 10 µL of 1µg/mL ampicillin (C). 
No inhibition halos were visualized for any extract. 
 
 
C 
C 
A 
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different extracts in DMSO+acetone (see section 3 from the methodology) and freeze 
dried for better preservation of the activity. Before use, they were dissolved in 2mL 
DMSO and tested against M. luteus in the screening described as the well assay, to 
allow higher concentration of extract tested (100 µL volume drops). However, no 
inhibition halos were visualized for any extract (Fig. 20). 
 
 
 
 
 
 
 
 
 
 
 Contrarily to what was observed in the preliminary screenings, where MsF2 and 
FF1 extracts inhibited M. luteus, neither the extracts obtained from the various types of 
stressed cultures nor the extracts from the repeated normal medium cultures presented 
antimicrobial activity against the chosen targets. Even the use of the well assay to 
allow 10 fold higher concentration of extract did not enhance the visualization of anti-
microbial activity. As in a previous study it was demonstrated that medium 
supplemented with NAG instead of glucose enhanced the production of secondary 
metabolite by Planctomycetes (Jeske et al, 2016), the two strains that already showed 
activity, FF1 and MsF2, were assayed under this medium composition. As previously, 2 
mL of cultures were extracted in DMSO/acetone (see section 3 from the methodology). 
To screen for antimicrobial activity, extracts were tested against M. luteus in the 
modified Kirby-Bauer assay, with 10 µL of extract used. However, no activity against 
this target was visualized in this assay.  
 
Fig. 20- Well assay where small scale extracts from Planctomycetes (from chemical stressed cultures) were tested 
against M. luteus, after 24h incubation at 37ºC. The control was 10µL of 10µg/mL ampicillin (C). No inhibition halos 
were observed for any extract, as it is exemplified with these two plates. 
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1.3. Diffusion assay with filter discs 
 
 Since the previous medium alterations used in the incubation of the strains did 
not potentiate the inhibitory capacity of the extracts, another modification to the 
antimicrobial screening was made to prevent possible evaporation or diffusion 
problems by the extracts. MsF2 was the strain chosen, since it was one of the two 
strains that already revealed antimicrobial activity in the preliminary screening. Thus, a 
fresh 20mL culture in M607 medium was incubated and 2 mL centrifuged and sterilized 
through a filter, making the filtrate extract (see section 3 from methodology). The 
extract was then tested using the diffusion assay against M. luteus and B. subtilis with 
filter discs filled with 100 µL. However, no inhibition of the growth of both targets was 
visualized for the Planctomycete extract (Fig 21).  
 
 
 
 
 
 
 
 
 
1.4. Co-culture assay 
 
 Due to absence of bioactivity of the extracts screened, it was decided to search 
for antimicrobial activity directly on live cultures of Planctomycetes. Fresh cultures of all 
marine Planctomycetes in agar medium M607 were incubated for 3 days and then 
overlaid with an extra layer of Lysogeny soft agar medium incorporated with a 
standardized culture of M. luteus (see section 5.5 from the methodology). After 
incubating for 24 at 30º C to allow the growth of M. luteus, no inhibition of the target 
was observed, even not near the colonies of Planctomycetes (Fig 22). 
 
C 
C 
Fig. 21- Diffusion assay with filter discs were MsF2 extract (E) was tested against B. subtilis (A) and M. luteus (B). The 
control was a filter disc filled with 10 µL of 0.1µg/mL ampicillin (C).  No inhibition was observed near the filter discs 
filled with the extract. 
A B 
E 
E 
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2. Up-scaled studies 
2.1. Liquid-liquid extraction with ethyl acetate 
 
 As almost none of the small-scaled screenings or the co-culture assay allowed 
the obtainment of bioactivity, up-scaled culturing was assayed. Thus, 500 mL cultures 
in medium M607 were therefore prepared. Due to the impossibility of making such 
higher volume cultures with all strains, MsF2, FF1, UC9 and Gr7 were the chosen 
ones, either because they presented antimicrobial activity in the preliminary screenings 
or by their previously mentioned potential (Graça et al., 2016) (the NaPDoS prediction 
pathway products for strains UC9 and Gr7 were, respectively, bacitracin and 
myxalamid, two known antibiotics). Furthermore, MsF2 was also cultured two more 
times, to try to enhance even more the production of the bioactive molecules: one in 
500 mL of medium M607 complemented with 1% of a solution of an autoclaved culture 
of Bacillus subtilis plus 1% of algae extract (M607+A+Bacillus) and another in 500 mL 
of medium M607 only complemented with 1 % of the same algae extract (M607+A). 
For all these higher volume cultures, artificial sea water was substituted by the sea 
salts, in preparation of the media. To extract compounds from these up-scaled cultures, 
another organic reagent was chosen: ethyl acetate. This solvent offers more benefits 
than DMSO and acetone, such as a higher strength of extraction and immiscibility with 
water (Siek 1978). Thus, the extracts from the prepared cultures were done with ethyl 
acetate as referred in the methodology (see section 4.1 from the methodology) and the 
solid residues obtained dissolved in 2mL DMSO and screened for antimicrobial activity 
in different assays.  
Fig. 22- Co-culture assay with live strains of Planctomycetes in M607 medium against M. luteus. No inhibition of the 
target was observed near the colonies of Planctomycetes (in pink). 
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2.1.1. Antimicrobial screening against B. subtilis and M. luteus 
 
 The modified Kirby-Bauer was firstly used to screen antimicrobial activity from 
the previous referred ethyl acetate extracts obtained from up-scaled cultures of the four 
Planctomycetes (MsF2, FF1, UC9 and Gr7), against both B. subtilis and M. luteus (with 
50 µL of each extract tested). MsF2 extracts from M607 and M607+A+Bacillus showed 
firstly antimicrobial activity (Fig 23). The rest of the extracts were later screened and 
the antimicrobial activity was also observed for all of them, including with the first 
referred two, which were also one more time assayed (Fig. 24). All extracts showed 
antimicrobial activity against the two targets, although in a more intense way against B. 
subtilis (Fig. 24). Both targets are Gram positive and sensitive bacteria but the 
antimicrobial action of extracts from these strains against B. subtilis was for the first 
time demonstrated in a solid medium assay, contrarily to M. luteus, which already 
showed susceptibility against Planctomycetes extracts since the preliminary 
screenings. The extract from MsF2 cultured in M607+A was the one showing the 
highest bioactivity against B. subtilis, compared to the ones obtained from MsF2 
cultured in M607 and M607+A+Bacillus (Fig. 24A). These results evidenced that the 
presence of algal material in the medium may influence positively the capacity of MsF2 
to produce bioactive antimicrobial compounds. However, when MsF2 was incubated in 
M607+A+Bacillus, the inhibition levels were similar to the ones of MsF2 incubated in 
normal M607. The solvent control (DMSO) did not present antimicrobial activity.  
 
 
 
 
 
 
 
 
 
Fig. 23- Modified Kirby-Bauer assay where up-scaled Planctomycetes extracts were tested against B. subtilis (A) and 
M. luteus (B), incubated at 37ºC for 24h. E1= ethyl acetate extract from MsF2 cultured in 500mL of medium M607; E2= 
ethyl acetate extract from MsF2 cultured in 500mL of medium M607+A+Bacillus; C= control of 10 µL of 1mg/mL 
ampicillin; D= control with 10 µL DMSO. Inhibition halos were observed for the two extracts. Control with DMSO did not 
present antimicrobial activity.  
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Fig. 24- Modified Kirby-Bauer assay where up-scaled Planctomycetes extracts were tested against B. subtilis (A) and 
M. luteus (B), incubated at 37ºC for 24h. E1= ethyl acetate extract from MsF2 cultured in 500mL of medium M607; 
E2= ethyl acetate extract from MsF2 cultured in 500mL of medium M607+A+Bacillus; E3= ethyl acetate extract from 
MsF2 cultured in 500mL of medium M607+A; E4= ethyl acetate extract from strain FF1 cultured in 500mL of M607 
medium; E5= ethyl acetate extract from strain Gr7 cultured in 500 mL of M607 medium; E6= ethyl acetate extract of 
strain UC9 cultured in 500 mL of M607 medium; C= control of  10 µL of 1mg/mL ampicillin; D= solvent control with 10 
µL DMSO. Inhibition halos were observed for all extracts against both targets, although more evident against B. 
subtilis. Against this target, strains FF1, Gr7 and UC9 showed more weakly inhibition halos. Extract from the strain 
MsF2 cultured in M607+A was clearly the one that presented a higher bioactivity. Control with DMSO did not present 
antimicrobial activity.  
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Another Planctomycete, strain UC49.1, was latter screened because it showed 
anticancer activity in studies performed in our laboratory (unpublished results). This 
Planctomycete was directly cultured in 500 mL of medium M607+A (prepared with 
natural sea water), extracted with ethyl acetate (see section 4.1 from methodology)  
and screened for antimicrobial activity with both modified Kirby-Bauer assay (10 µL of 
the extract dissolved in DMSO) and diffusion assay with filter discs (50 µL of the extract 
dissolved in DMSO), against B. subtilis and M. luteus. However, no inhibitory effect 
against the two targets was observed, contrarily to the previous 4 strains tested (Fig. 
25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2. Antimicrobial screening against Chlamydia trachomatis 
 
 The antimicrobial screening with the obtained ethyl acetate extracts (dissolved 
in DMSO) from 4 of the marine strains (MsF2 in M607+A, FF1 in M607, Gr7 in M607 
and UC9 M607) was also performed against another target, Chlamydia trachomatis. 
This strain belongs to the phylum Chlamydiae, a member of the Planctomycetes, 
Verrucomicrobia and Chlamydiae (PVC) super-phylum. This is an interesting screening 
Fig. 25- Diffusion assay with filter discs filled with the UC49.1 up-scaled culture extracted with ethyl acetate (dissolved 
in DMSO), tested against B. subtilis (A) and M. luteus (B) and incubated for 24h at 37º C: C= control of 10 µL of 
1mg/mL ampicillin; D= control of 50 µL of DMSO; E1= 50 µL of the ethyl acetate extract of strain UC 49.1 cultured in 
500mL of M607. A very slightly inhibition halo was observed in both plates, for the extract of this strain.   
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due to the phylogenetic proximity of these bacteria. On another hand, infections with 
this pathogen (which causes one of the most prevalent sexual transmittable diseases) 
are still a concern due to the appearance of resistant strains and need urgent 
alternative treatments (Horner 2016). 
 Due to the intracellular activity of C. trachomatis, cells from the eukaryotic line 
Hep2 were firstly infected with this pathogen, exposed to several different treatments 
(Planctomycetes extracts within two dilutions, positive control of ciprofloxacin and 
solvent control of DMSO), stained for chlamydial lipopolysaccharides (LPS), host cell 
DNA and host cell cytoplasm and analyzed through fluorescence microscopy (see 
section 5.6 from the methodology).  
 In the untreated control (Figs. 26A and 27A) it was well evident the normal 
formation of chlamydial inclusions (in green) inside the host Hep2 cells. On the other 
hand, infected cells treated with the antibiotic ciprofloxacin (Figs. 26B and 27B) 
revealed a strong decrease of the chlamydial inclusions.  
 No effect in the chlamydial infection was observed for the less concentrated 
extracts from Planctomycetes (1.28 µL dilution) as well as for the solvent control 
(DMSO) at the same quantity (Figs 1 and 2 from the attachments). However, when 
infected cells were exposed to the more concentrated extracts from Planctomycetes 
(2.56 µL) (Figs. 26E,F and 27E,F), several levels of chlamydial inhibition were 
observed, except for strain FF1, for which the infection level was similar to the 
untreated control (Fig. 26E), where the green color of inclusions is observed inside the 
host cell. UC9 showed a certain reduction in the size and number of chlamydial 
inclusions (Fig. 26F). MsF2 and specially Gr7 induced both a great inhibitory activity, 
with effects similar to the control of cells treated with ciprofloxacin (Figs. 27E and 27F). 
Effects provoked by strain Gr7 presented even more similarity with the control of non-
infected cells (Fig. 27D), as practically no green of chlamydial LPS is observed.  
 These promising results, however, have to be taken with care since the solvent 
control of DMSO (at 2.56 µL dilution) also revealed a reaction on the chlamydial 
inclusions development (Figs. 26C and 27C). Yet, by the comparison of this control and 
the extract from Gr7 strain, chlamydial action may be present, although no exact 
distinction can be made between the effects of the Planctomycete extract and the 
DMSO in which it was dissolved. 
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Fig. 26 - Fluorescence microscope images of eukaryotic cells from line Hep2 infected with Chlamydia trachomatis and 
exposed to several treatments, as ciprofloxacin and the 2.56 µL extracts from Planctomycetes strains UC9 and FF1. 
Blue correspond to DAPI staining of DNA from the host cells, green to chlamydial inclusions and red to host cell 
cytoplasm.  A= control of untreated infected cells; B= control of infected cells treated with 1µg/mL ciprofloxacin; C= 
infected cells exposed only to 2.56 µL DMSO dissolved in sterile water; D= Control of non-infected cells; E= infected 
cells exposed to 2.56 µL extract of strain FF1; F= infected cells exposed to 2.56 µL extract of strain UC9. No effect of 
FF1 extract against the chlamydial infection was visualized at this quantity. On the other hand, cells treated with 2.56 
µL of only DMSO presented a diminution in the chlamydial inclusions to a few small round structures. Cells exposed to 
extract from strain UC9 presented a diminution on the inclusions similar with the control with DMSO, so this anti-
microbial activity may be due to the solvent.  
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Fig. 27 - Fluorescence microscope images of eukaryotic cells from line Hep2 infected with Chlamydia trachomatis and 
exposed to several treatments, as ciprofloxacin and the 2.56 µL extracts from Planctomycetes strains Gr7 and MsF2. 
Blue correspond to DAPI staining of DNA from the host cells, green to chlamydial inclusions and red to host cell 
cytoplasm.  A= control of untreated infected cells; B= control of infected cells treated with the antibiotic 1µg/mL 
ciprofloxacin; C= infected cells exposed only to 2.56 µL DMSO dissolved in sterile water; D= Control of non-infected 
cells; E= infected cells exposed to 2.56 µL extract of strain MsF2; F= infected cells exposed to 2.56 µL extract of strain 
Gr7. Cells exposed with the extracts from strains MsF2 and Gr7 showed almost a total effect of a controlled infection, 
which is demonstrated by their similarity with the cells exposed to the control antibiotic ciprofloxacin. In the case of strain 
Gr7, the similarity is even bigger with the control of cells with no chlamydial infection, since practically no green is 
observed inside the cells. However, as the control of DMSO also showed antimicrobial action, the exact effect of the 
extracts can’t be determined. 
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2.1.3. Mode of action assay 
 
 In order to search for the cellular targets of the potential compounds in the 
Planctomycetes extracts, a mode of action assay was performed. Four different B. 
subtilis reporter strains (designed for the 4 main bacterial targets: cell wall, DNA, RNA 
and protein synthesis) were exposed to the previous extracts dissolved in DMSO 
obtained from the extraction of the 500 mL cultures of the 4 marine strains MsF2, FF1, 
UC9 and Gr7. Inhibition halos were visualized for all extracts of Planctomycetes, 
confirming the presence of bioactive compounds and showing once more that the 
extract from strain MsF2 cultured in medium M607+A was the most bioactive one (Figs. 
28 and 29). On the other hand, as no blue color appeared around any of the inhibition 
halos, no conclusion can be drawn on the mode of action behind the compound 
responsible for the bioactivity. Only the antibiotic tetracycline showed a slight blue 
coloration against the protein target (Fig. 28), while and no other antibiotic control 
showed the same effect, as it is exemplified for cell wall and DNA targets (Fig. 29A and 
B). Since the blue color was also not very robust for the several controls, it is 
suggested that the concentration of X-Gal was probably too low or that this substance 
was possibly degraded.  
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Fig. 28- Mode of action assay where Planctomycetes extracts were tested against Bacillus subtilis 128 transformed 
with pAC6-vector containing the promotor PyheI (for protein target), incubated for 24h at 37º C. E1= extract MsF2 
cultured in 500mL of M607 medium; E2= extract of MsF2 cultured in 500mL of medium M607+A+Bacillus; E3= 
extract of MsF2 cultured in 500mL of medium M607+A; E4= extract from FF1 cultured in 500mL of M607 medium; 
E5= extract from strain Gr7 cultured in 500 mL of M607 medium; E6= extract from strain UC9 cultured in 500 mL of 
M607 medium; C1= control of 500 µg/mL tetracycline; D= control with only DMSO.  Inhibition halos were observed for 
all extracts, with MsF2 incubated in M607+A the most bioactive one. Control with DMSO presented a small effect, 
however. No blue residues were visualized besides in the halo from the antibiotic control C1 (arrow).  
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Fig. 29-  Mode of action assay where Planctomycetes extracts were tested against Bacillus subtilis 128 transformed 
with pAC6-vector containing the promotor PypuA (for cell wall target) (A) or the promotor PyorB (for DNA target) (B), 
incubated for 24h at 37º C. E1= extract MsF2 cultured in 500mL of M607 medium; E2= extract of MsF2 cultured in 
500mL of medium M607+A+Bacillus; E3= extract of MsF2 cultured in 500mL of medium M607+A; E4= extract from 
FF1 cultured in 500mL of M607 medium; E5= extract from strain Gr7 cultured in 500 mL of M607 medium; E6= 
extract from strain UC9 cultured in 500 mL of M607 medium; C2= control of 500 µg/mL ampicillin; C3= control of 500 
µg/mL vancomycin; D= control with only DMSO.  Inhibition halos were observed for all extracts and extract from the 
strain MsF2 cultured in M607+A was the most bioactive one. Control with DMSO did not showed bioactivity. No blue 
residues were visualized. 
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2.1.4. Gel permeation chromatography 
 
 The capacity of Planctomycetes to produce bioactive compounds with 
antimicrobial activity was observed in the previous assays, confirming their genetic 
potential previously recognized (Graça et al., 2016). Strains MsF2 and Gr7 were 
therefore chosen for the beginning of compound isolation by gel permeation 
chromatography (GPC), based on the earlier obtained results (MsF2 was the most 
consistently bioactive strain and Gr7 showed promising chlamydial activity). Thus, 
newly cultured MsF2 and Gr7 in medium M607+A (this time, prepared with natural sea 
water) were extracted with ethyl acetate and dissolved in methanol, since it is the 
solvent used in the chromatography (see section 6 from methodology). They were then 
firstly screened for antimicrobial action, before fractionation. As strain Gr7 showed a 
more pronounced halo than MsF2 (Fig. 30), it was decided to continue for separation 
with Gr7 extract. 
 
 
 
 
 
 
 
 
 
 To fractionate the heterogeneous extract obtained from strain Gr7, the column 
used was Sephadex LH20, chosen by its normal use to separate terpenoids and small 
weight peptides. Fractions were collected every 15 minutes, from minute 0 to minute 
225, dried and at the end screened for antimicrobial activity against B. subtilis and M. 
luteus using the well assay, to allow the use of a higher volume of each fraction (100 
µL). However no fraction showed bioactivity against the two targets (Fig. 31), which 
suggests that the concentration of compound extracted was probably too low for 
isolation and further detection of activity.  
E1 E2 
Fig. 30- Modified Kirby-Bauer assay where extracts from strains MsF2 and Gr7 where tested against B. subtilis, 
incubated for 24h at 37º C. E1= extract from MsF2 cultured in 500 mL of medium M607+A; E2= extract from strain Gr7 
cultured in 500 mL of M607+A. A more pronounced inhibition halo was observed in the spot of the extract from strain 
Gr7.  
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2.2. Extraction with methanol 
  
 As the previous separation did not allow the obtainment of a bioactive fraction, 
enhancement of the compound production levels by Planctomycetes strains was 
required. Thus, another alternative extraction method was assayed for the strain that in 
the previous assays showed a higher bioactivity: strain MsF2. Another up-scaling was 
also intended, so a culture of this strain was prepared in 2L of medium M607. Methanol 
was the chosen organic solvent to extract possible compounds from the cells of this 
culture (Leão et al., 2013). The extract obtained (Fig. 32A) was subsequently screened 
for antimicrobial activity with the diffusion assay with filter discs against B. subtilis. 
Unfortunately, no inhibition halo was visualized for this extract (Fig. 32B).  
Fig. 31- Well assay where fractions obtained from Gr7 extract subjected to GPC were tested against B. subtilis (A and 
B) and M. luteus (C and D), incubated for 24h at 37º C. C= control of 10 µL of 1mg/mL ampicillin; M= control of 100 
µL methanol. No inhibition halo was observed for any fraction. Control with methanol did not present any inhibition,  
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2.3. Incubation of cultures with XAD resin and extraction with 
acetone and ethyl acetate 
 
 Since the antimicrobial activity by MsF2 strain was not recovered with the lastly 
applied protocol, other modifications were tried. One more up-scaling was also done, 
for which a 3L culture of strain MsF2 was prepared in medium M607. To allow the 
accumulation and further extraction of compounds possibly present in the aqueous 
phase of this culture, resin Amberlite® XAD16N was added to it in the late exponential 
phase. This resin is specifically designed to adsorb and hold hydrophobic compounds 
up to 40,000 MW such as antibiotics. To extract from this resin, two different protocols 
were used, one using ethyl acetate and another using acetone, as is described in the 
methodology (see section 4.3 of the methodology). Acetone was used because it has 
been also used in a study to extract bio compounds from other strains of 
Planctomycetes (Jeske et al., 2016). The culture (that remained after separation of the 
resin) was centrifuged and the cells pellet extracted with ethyl acetate. The extraction 
of the resin with ethyl acetate was the one that resulted in more solid residue after 
Fig. 32- A= Methanol extract obtained from the 2L culture of strain MsF2 prepared in medium M607, dissolved in 
2mL DMSO and 1 mL methanol; B= Diffusion assay with filter discs where MsF2 extract was tested against B. 
subtilis, incubated for 24h at 37º C: C= control of 10 µL of 1mg/mL ampicillin; M= control of 50 µL methanol; E= 
Filter disc filled with 50 µL of the methanol extract represented in (A). No inhibition halo was visualized in the filter 
disc with the extract.  
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evaporation (Fig. 33A). The three extracts obtained (Fig. 33B) were consequently 
screened for antimicrobial activity against B. subtilis using the diffusion assay with filter 
discs (resin extracts) and the modified Kirby-Bauer assay (cell pellet extracts). 
However, no inhibition halos were observed for any extract (Fig. 34).  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 34- Diffusion assay with filter discs and modified Kirby-Bauer assay where MsF2 resin (A) and cell pellet (B) 
extracts were tested against B. subtilis, incubated for 24h at 37º C. C= control of 10 µL of 1mg/mL ampicillin; M= 
control of 50 µL of methanol; E1= Filter disc filled with 50 µL of ethyl acetate extract from the resin incubated with 
strain MsF2 in 3L of medium M607; E2= Filter disc filled with 50 µL of acetone extract from the resin incubated with 
strain MsF2 in 3L of medium M607; E3= filter disc filled with 50 µL of the extract from the cells obtained from  a 3L 
culture of strain MsF2 in medium M607. No inhibition halos were visualized for any extract. 
A 
B 
C 
E2 
E1 
M 
E3 
M 
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A B 
Fig. 33- A= solid residues obtained from the ethyl acetate extraction of the resin, after drying in a rotatory evaporator; 
B=three different extracts obtained from the 3L culture of strain MsF2 in medium M607 incubated with resin 
Amberlite® XAD16: a) extract of the resin with ethyl acetate, dissolved in 5 mL of methanol; b) extract of the resin with 
acetone, dissolved in 8 mL of methanol; c) extract of the cells pellet of the culture with ethyl acetate, dissolved in 2 mL 
of methanol. 
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a) b) c) 
FCUP 
Exploring the secondary metabolite potential of Planctomycetes from marine and freshwater environments 
67 
 
 
2.4. Exploring the potential of freshwater strains 
 
 Two strains of Planctomycetes isolated from freshwater sediments were also 
screened for antimicrobial activity (based on the genetic potential revealed by 
Aquisphaera giovannonii OJF2, as AntiSMASH analyses showed 52 genes clusters for 
secondary metabolite production in this species). These two strains (OJF2 and OJF8) 
were directly incubated in an up-scaled culture of 1 L of PYGV medium and extracted 
using ethyl acetate, since it was the solvent that permitted the visualization of activity 
with the previous strains. To evaluate activity, the extracts obtained were tested in 
diffusion assay with filter discs against B. subtilis (both OJF8 and OJF2) and M. luteus 
(only OJF8). A small inhibition halo was visualized in the extract of strain OJF8 against 
both targets (Fig. 35A and 35B). A repetition of the assay was made against B. subtilis 
and the activity was once more visualized (Fig. 35C), confirming the potential of this 
strain. However, the extract from strain OJF2 did not present antimicrobial activity (Fig. 
35D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 35- Diffusion assay with filter discs where freshwater Planctomycetes extracts were tested against B. subtilis (A, C 
and D) and M. luteus (B), incubated for 24h at 37º C. E1= Filter disc filled with 100 µL of the extract obtained from 
strain OJF8 in medium  PYGV; E2= Filter disc filled with 100 µL of the extract obtained from strain OJF2 in medium 
PYGV; C= Filter disc filled with 10 µL of the control of 1 mg/mL ampicillin; D= Filter disc filled with 10 µL of the control 
of DMSO. Inhibition halos were visualized for OJF8 extract against both targets. However, no inhibition halo was 
visualized for strain OJF2. 
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3. Anti-obesity assay with zebrafish larvae 
 
 Besides the search for antimicrobial activity focused in this thesis, anti-lipid 
production activity was also explored for Planctomycetes extracts, having in mind the 
obesity problematic in current times. 
 For this assay, 9 marine Planctomycetes were chosen (UC16, UC9, Rb, CcC6, 
MsF2, FF1, Gr7, UC 49.1 and UC13) and incubated in an intermediate volume in 
medium M607 (100 mL), due to the impossibility of making higher volume cultures for 
all strains at the same time. Cultures were then used for extraction with ethyl acetate 
and the extracts dissolved in DMSO standardized to the 10 mg/mL concentration, to a 
more precise comparison (see section 5.8 from the methodology). Larvae of zebrafish 
were also obtained and exposed to several treatments (Planctomycetes extracts, 
positive control of resveratrol and solvent control of DMSO) in 48-well plates and 
stained for lipid drops with Nile red. Larvae were then analyzed under fluorescence 
microscopy and the levels of the inhibitory capacity against lipid production calculated 
for each treatment, using the mean fluorescence intensity values obtained from the 
images analyzes with the software ImageJ.  
 Larvae exposed to the solvent control (DMSO) presented a normal lipid 
production, since lipid drops stained with Nile red were observed under fluorescence 
microscopy, mostly under the larvae abdomen (Fig. 37B). DMSO was also chosen as 
negative control, since this compound does not affect lipid production in zebrafish and 
is normally used as control in these assays (Jones et al., 2008). The mean valor of the 
inhibition calculated for all larvae exposed to this treatment was therefore considered 
as 100 % of lipid production/accumulation and subsequently taken as 0 % of inhibitory 
capacity of lipid production.  
 On the other hand, larvae exposed to the positive control resveratrol 
demonstrated no lipid production, since no red staining was observed, as expected 
(Fig. 37D). This compound can be used as example to show effect on the lipid 
production in zebrafish (Jones et al., 2008) and its action against mice fat was also 
proven (Lagouge et al., 2006). However, resveratrol seems not to show any effect on 
humans (Alberdi et al., 2014 and Poulsen et al., 2013),  
  All larvae exposed to Planctomycetes extracts presented different levels of 
intensity of fluorescence, although red staining of lipid drops was always present 
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(larvae exposed to strain UC9 exemplified in Fig. 37F), which means that no total 
inhibition of the lipid production/accumulation occurred.  After statistic treatment of the 
data obtained and calculation of the exact mean percentage of inhibition for each 
extract exposure (by comparison with the DMSO control), it was confirmed that no 
Planctomycete extract inhibited in the totality the lipid production, although all 
presented positive activity (Fig. 36). All treatments were also statistically different from 
each other (F[8,62 ]= 6.98; p < 0.05). Most extracts showed lower values of inhibition of 
lipid production/accumulation, between 3 % and 20 % (Fig. 36). On the other hand, 
values of 30 % and 36 % inhibition were obtained, respectively, for extracts from 
strains CcC6 and MsF2, which are affiliated to Rhodopirellula lusitana and 
Rhodopirellula baltica species. These two were the only ones significantly different 
from the DMSO control (Fig. 36), meaning that their inhibition values showed could be 
considered. Unfortunately, no larvae exposed to FF1 extract survived the experience 
(maybe due to the manipulation) and consecutively its results were not considered.   
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Fig. 36- Inhibition of lipid production/accumulation (%) in larvae of zebrafish exposed for 48h to Planctomycetes 
extracts, to the control compound resveratrol and to the solvent control DMSO. Error bars were obtained from the 
calculus of standard error of the mean value. Inhibition values were mostly low, with CcC6 and MsF2 the only ones 
equal or above 30%. Resveratrol, as expected, produced 100 % of inhibition. **= Dunnett’s test performed to the 
treatments in comparison with the solvent DMSO control showed that CcC6 and MsF2 values were significantly 
different (p<0.01) and their inhibitory values could be considered. 
 ** 
  ** 
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Fig. 37- Contrast phase (A, C and E) and fluorescence (B, D and F) microscope images of larvae of zebrafish exposed 
to several treatments and stained with 50 µL of 500 ng/mL Nile red (red): A,B= exposure for 48h to 200 µM PTU and to 
0.75 µL DMSO; C,D= exposure for 48h to 200 µM PTU and to 0.75 µL of 11.412 mg/mL resveratrol; E,F= exposure for 
48h to 200 µM PTU and to 0.75 µL of  the extract from strain UC9 dissolved in DMSO (10 mg/mL). For Nile red, 
excitation wavelength: between 515 and 560 nm and emission wavelength > 590 nm. Control with resveratrol inhibited 
the lipid production, as is seen by the absence of red color (D).  On the other hand, solvent control with DMSO showed 
total lipid production and accumulation, as is seen by the presence of red residues mostly in the larvae abdomen (B). 
Extract from strain UC9 did not totally inhibit the lipid production, as is demonstrated by the presence of red coloration 
(F).  
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Discussion 
  
 Previous works (Graça et al., (2016) and Jeske et al., (2016)) showed the 
potential of Planctomycetes to produce antimicrobial compounds. A subsequent step 
for the characterization of precise molecules behind the activity is the fractionation of 
extracts for isolation of the compounds. In this work, we aimed to achieve this goal and 
search for the secondary metabolite potential of several aquatic strains of 
Planctomycetes.  
 To do a preliminary screening of the antimicrobial action by Planctomycetes, 
one assay was initially made in liquid medium (the 96-well assay). This assay was in a 
small scale, since only 2mL of small cultures (20mL) were used to make extracts, and 
where metabolites were extracted with DMSO+acetone. The high bioactivity obtained 
in the screenings against B. subtilis with twelve of the marine strains showed 
consistency with results from Graça et al., (2016), where other marine strains of 
Planctomycetes presented also activity against this target strain. Against the tested E. 
coli, which is a very resistant strain isolated from a high polluted river (Cabral & 
Marques, 2006), no activity was observed for any of the extracts. Once again, these 
results are consistent with the ones from the same referred study. However, activity 
against C. albicans was not visualized in the present study, contrarily to the anti-fungal 
activity demonstrated also by Graça et al., (2016). This result may be due to a 
metabolic alteration of this target strain or to the development of antimicrobial 
resistance. These first twelve screened strains were isolated from the biofilm of three 
different macroalgae, however, they are all phylogenetically related to Rhodopirellula 
baltica, which confirms the potential associated to this species. In fact, Jeske et al., 
(2016) also found antimicrobial activity against of R. baltica against B. subtilis.  
 In order to complement this initial screening, the modified Kirby-Bauer was used 
to evaluate the antimicrobial activity of an enlarged panel (35 strains) of 
Planctomycetes, against two sensitive targets, B. subtilis and M. luteus, within the 
same extraction protocol. However, only two inhibition halos were observed against M. 
luteus (FF1 and MsF2 pellet extracts) and none against B. subtilis, which is contrary to 
the activity that was evidenced in the previous assay with the same type of extracts.  
 The production of secondary metabolites is normally very inconsistent and 
dependent on many factors, such as the medium composition, stress conditions and 
the growth phase (Bibb 2005). Since the extracts tested in the modified Kirby-Bauer 
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assay were prepared after the beginning of the internship in Bonn using artificial sea 
water for medium preparation, the lack of activity demonstrated may be due: (1) to this 
modification, (2) to bacterial stress caused by the transportation between the two 
countries or (3) simply to the differences between the two assays. Several 
modifications to the medium composition were made, which included biological, 
chemical and organic stresses as well as natural environment simulation (done with the 
incorporation of macroalgal extract in the medium). These modifications were 
ineffective in recover and inducing the secondary metabolite production in small scale, 
which results are hardly justifiable.  
 As bioactivity seemed to vanish when extracts were made, co-culture assay 
was tested with live cultures of Planctomycetes, which avoid extraction. Once again, no 
activity from Planctomycetes could be observed. However, these results may be due to 
the short period (3 days) of strains incubation. Normally, Planctomycetes cultures with 
3 days growth are in the beginning of the stationary phase and the secondary 
metabolism could there not yet been activated. The difference in the incubation time in 
this specific assay was due to time constrains and accessibility of laboratory facilities.    
 Since the production of compounds by marine Planctomycetes was not 
enhanced by the previous alterations, new protocols were tested. The culturing and 
extracting of the bacteria were up-scaled from a small scale (with 2 mL extracted from 
20 mL cultures) to 500 mL cultures entirely extracted. Another solvent was also used 
for extraction to substitute the previously used mixture of DMSO+acetone, ethyl 
acetate. The four Planctomycetes assayed were chosen either because of their activity 
already demonstrated (FF1 and MsF2) or their genetic potential (UC9 and Gr7). Both 
UC9 and Gr7 have been screened by Graça et al., (2016) for the presence of 
PKS/NRPS genes. These genes encode for two major enzyme complexes that are 
responsible for the majority of the secondary metabolites production (Donadio et al., 
2007), thus, their presence may be an indicator of possible metabolites of interest. Gr7 
and UC9 were also screened for their potential pathway product prediction, using the 
NaPDos software (which is a bioinformatic tool for the rapid detection and analysis of 
secondary metabolite genes). The products predicted were, for Gr7 and UC9 
respectively, myxalamid (only observed for Myxobacterales) and bacitracin, both 
known compounds with antimicrobial activity. The analyzes with AntiSMASH software 
(an antibiotic and secondary metabolite analyses shell) to Gr7 genome showed eight 
gene clusters for these types of metabolites in which two leaded to potential 
antimicrobial compounds with biotechnological interest: bacteriocins and lantipepetides 
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(Yang et al., 2014; Field 2015). In these up-scaled tests, where the solvent used for 
extraction was ethyl acetate, we were able to detect bioactivity for all extracts against 
B. subtilis and M. luteus, although more powerfully against B. subtilis. It was noted that 
M. luteus developed some resistances since the beginning of its utilization, as it was 
confirmed by the necessity of using a control of ampicillin with higher concentration. 
This acquired resistance may be the responsible for that differential strength of 
inhibition, since both targets are Gram positive bacteria and very sensitive to external 
compounds.  
 In an attempt to increase the bioactive potential observed for strain MsF2, the 
more bioactive strain of the four screened, an up scaled culture in medium variations of 
M607+A and M607+A+Bacillus were assayed. Under these conditions, we were able to 
have a high degree of bioactivity (especially on MsF2 culture in M607 plus algal 
extract, which was the higher activity obtained in this work). These results indicate that 
the use of higher volumes for extraction is an important factor as well as the stimulation 
of the Planctomycetes by the presence of material from their natural host, the 
macroalgae (Lage & Bondoso, 2014).  
 Furthermore, as the previous ethyl acetate extracts obtained showed bioactive 
potential, they were screened against C. trachomatis. Again, MsF2 as well as Gr7 
showed anti-chlamydial activity by reducing the formation of chlamydial inclusions 
inside the host cells. However, the control with the solvent also showed reduction of 
chlamydial inclusions. Thus, as the exact effect of the DMSO can’t be distinguished 
from the extracts effects, more studies are needed, ideally with a purified compound or 
extracts dissolved in water, to resolve this solvent problem and confirm the potential 
activity.   
 Although the genetic potential revealed by Aquisphaera giovannonii OJF2 
(AntiSMASH analyses showed 52 genes clusters for secondary metabolite production), 
the screening with the two strains from this species (OJF2 and OJF8) only revealed a 
small level of bioactivity for strain OJF8, even though the extraction was made to 1000 
mL of culture and using ethyl acetate.  
 Additional protocols of extraction comprehending different methodologies (more 
culture up-scaling, methanol as solvent for cell pellet extraction, incubation/extraction 
with a resin and cell pellet extraction with ethyl acetate) were tested to try to recover 
the activity once observed by strain MsF2. However, no antimicrobial action was 
visualized in any of these protocols. Besides the high diversity of screening approaches 
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and extraction techniques assayed during this study, it was not possible to achieve a 
good optimized protocol for the subsequent step of bioactive molecules isolation from 
Planctomycetes using gel permeation chromatography. 
 Regarding the anti-obesity assay, no final conclusive results can be taken about 
the capacity of Planctomycetes to inhibit the lipid production and accumulation, since 
the extracts used where from low volume cultures (100 mL) potentially with low amount 
of the metabolites of interest within the heterogeneous mixture, in which the pretended 
action could have been masked. However, strains MsF2 and CcC6 presented under 
these conditions significative anti-obesogenic activity equal or above 30 %, which is 
promising. These results encourage further studies, like a repetition of this assay with 
extracts obtained from an optimized protocol or ideally with purified compounds 
(Noinart et al., 2017), if possible, to more correctly evaluate this capacity and confirm 
the potential demonstrated for new anti-obesogenic metabolites.    
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Conclusion 
 
 Antimicrobial activity was observed against B. subtilis and M. luteus for extracts 
obtained from different Planctomycetes species: Rhodopirellula baltica, Rhodopirellula 
rubra, Aquisphaera giovannonii and Rubinisphaera brasiliensis. Assays that evaluated 
anti-Chlamydia trachomatis and anti-obesity activities by Planctomycetes metabolites 
showed promising results, but regarding additional studies. Besides the high diversity 
of screening approaches and extraction techniques assayed, it was not possible to 
achieve a good optimized protocol for the subsequent step of bioactive molecules 
isolation from Planctomycetes using gel permeation chromatography. 
 Future perspectives on this work are based on the optimization of the protocol 
of culturing and extraction of Planctomycetes, in order to regain the activity of the used 
strains. The use of revival Planctomycetes strains from the -80ºC collection would be a 
good practice, since the ones used have already been subcultured for some time, 
which may imply loss of activity through time. The same is suggested for the target 
strains, since potential resistance acquisition may be interfering with the antimicrobial 
detection. A relevant culture up-scaling (10 to 20L) is also proposed, as well as the re-
test of sea salts in the medium preparation, since no exact information of the natural 
sea water composition is known. The use of the resin Amberlite® XAD16N within the 
Planctomycetes incubation is also suggested because it allows the accumulation of 
compounds present in the aqueous phase of cultures. For the extraction of 
compounds, it is proposed to continue the use of ethyl acetate as solvent for crude 
culture extraction (organic soluble metabolites) and for resin extraction (aqueous 
soluble metabolites).  
 Furthermore, compounds isolation and determination of their mode of action are 
important steps to allow subsequent analyses to their structures and viability to be used 
in pre-clinical trials. 
 New and/or optimized anti-Chlamydia trachomatis and anti-obesity tests are 
needed to confirm the obtained results and to step forward to potential use of the 
bioactive extracts. 
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Fig. 1- Fluorescence microscope images of eukaryotic cells from line Hep2 infected with Chlamydia trachomatis and 
exposed to several treatments, as ciprofloxacin and the 1.28 µL extracts from Planctomycetes strains Gr7 andMsF2. 
Blue color corresponds to the DAPI staining of DNA from the host cells, green to chlamydial inclusions and red to host 
cell cytoplasm.  A= Control of untreated cells; B= Control of cells treated with the antibiotic ciprofloxacin (at 1µg/mL); C= 
Cells exposed only to 1.28 µL DMSO dissolved in sterile water; D= Control of non-infected cells; E= Cells exposed to 
1.28 µL extract of strain Gr7; F= Cells exposed to 1.28 µL extract of strain FF1. No effect of both FF1 and Gr7 extracts 
in the chlamydial infection was visualized at this quantity, since the aspect of the inclusions (green) is similar with the 
control of untreated cells (A).  
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Fig. 2-  Fluorescence microscope images of eukaryotic cells from line Hep2 infected with Chlamydia trachomatis and 
exposed to several treatments, as ciprofloxacin and the 1.28 µL extracts from Planctomycetes strains UC9 and FF1. 
Blue color corresponds to the DAPI staining of DNA from the host cells, green to chlamydial inclusions and red to host 
cell cytoplasm.  A= Control of untreated cells; B= Control of cells treated with the antibiotic ciprofloxacin (at 1µg/mL); 
C= Cells exposed only to 1.28 µL DMSO dissolved in sterile water; D= Control of non-infected cells; E= Cells exposed 
to 1.28 µL extract of strain MsF2; F= Cells exposed to 1.28 µL extract of strain UC9. No effect of both UC9 and MsF2 
extracts in the chlamydial infection was visualized at this quantity, since the aspect of the inclusions (green) is similar 
with the control of untreated cells (A).  
